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 PREFACE  
Medicinal chemistry thus forms the chemical basis of therapeutics. Interdisciplinary 
science. It has been stated   that “Medicinal chemistry concern the discovery, the development, the 
identification and interpretation of the mode of action of biologically active Compounds at the 
molecular level”. Evidently it touches all branches of Chemistry and biology. Medicinal chemistry 
has interfaces with pharmaceutical chemistry, molecular pharmacology, bio-organic chemistry, 
and selective toxicity. Medicinal chemistry is a chemistry-based discipline, which involves 
aspects of biological, medical and pharmaceutical sciences. 
       It is concerned with the invention, discovery, design, identification and preparation of 
biologically active compounds, the study of their metabolism, the interpretation of their mode of 
action at the molecular level and construction of structural activity relationships by which they 
can be used as a medicine for the prevention mitigation and treatment of diseases. 
      The focus is mainly on organic medicinal substances. The organic drugs may be of natural or 
synthetic origin. The synthetic drugs have resulted by simple or mere modification of the 
structures of the natural drugs, or by pure synthesis. The other areas of collaboration in medicinal 
chemistry includes biology, computer aided drug design (CADD), 3-D QSAR, X-ray 
crystallography, metabolism, pharmacokinetics, legal and regulatory affairs, clinical franchise  
management, pharmaceutics and process research chemistry.  
  
     The practice of medicinal chemistry is devoted to the discovery, development of new 
agents for treating diseases. Most of the activity in this is devoted to new natural or synthetic 
organic compounds. The process of establishing a new drug is exceedingly complex and involves 
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the talents of people from a variety of disciplines, including chemistry, biochemistry, physiology, 
pharmacology, pharmaceutics and medicine. Medicinal chemistry is concerned mainly with the 
organic analytical and biologic interface of chemistry and biology. There is a considerable overlap 
with chemical aspects of this process. Thus it occupies a strategic position at the other disciplines. 
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                                                               INTRODUCTION 
TUBERCULOSIS 
Mycobacterium tuberculosis  MTB, or TB (tubercle bacillus), in the past also 
called Phthisis or Phthisis pulmonalis, and colloquially, consumption or tisic, is a common, and in 
many cases lethal, infectious disease caused by various strains of mycobacteria, 
usually Mycobacterium tuberculosis.
[1]
Tuberculosis typically attacks the lungs, but can also affect 
other parts of the body. It (identified by Koch in 1882) is the first bacteria recognized as causative 
agent for tuberculosis.
 [2]
 The dramatic importance of this still present illness is well known
 [3]
. It is 
spread through the air when people who have an active TB infection cough, sneeze, or otherwise 
transmit respiratory fluids through the air.
 [4]
 Over the past 200 years, tuberculosis was responsible 
for the death of 100 million people.
 [5]
   
The Mycobactenum tuberculosis complex constitutes a genetically closely related group, 
and its members, M. tuberculosis, Mycobactenum afncanum, Mycobactenurn bovis, and 
Mycobacterium microti, may be considered as subspecies of M. tuberculosis
 [6, 7]
. The close 
relation between M. tuberculosis complex bacteria has been established by DNA-DNA 
hybridization (>95%) (l), multiple-locus enzyme electrophoresis
 [8]
, and Sequencing of 16s 
ribosomal RNA and housekeeping genes. 
[9]
 Furthermore, repetitive DNA elements, such as the 
insertion sequence IS6110 and the direct repeat have been found restricted to the M. tuberculosis 
complex, Nevertheless
 [10]
.the host range and pathogenicity of the M. tuberculosis complex 
species vary enormously. The natural reservoir of M. tuberculosis and M. afncanum is limited to 
humans.
 [11, 12]
 In contrast, the host range of M. bovis is very broad, and this species causes disease 
among a wide range of wild and domestic mammals as well as in humans.
 [13]
 
 
HISTORY OF TUBERCULOSIS 
Tuberculosis has been present in humans since antiquity .
 [14]
 In order to assess the 
presence of tuberculosis in Pleistocene bison and the origin of tuberculosis in North America, 2 
separate DNA extractions were performed by 2 separate laboratories on samples from the 
metacarpal of an extinct long-horned bison that was radiocarbon dated at 17,870 ± 230 years 
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before present and that had pathological changes suggestive of tuberculosis.
 [15
and researchers 
have found tubercular decay in the spines of Egyptian mummies dating from 3000–2400 BC. 
[16]
 Phthisis is a Greek word for consumption, an old term for pulmonary tuberculosis;
 [17]
 around 
460 BC, Hippocrates identified phthisis as the most widespread disease of the times.
 [18]
  
Tuberculosis has claimed its victims throughout much of known human history.
 [19]
 It 
reached epidemic proportions in Europe and North America during the18th and 19th centuries, 
earning the sobriquet, „„Captain Among these Men of Death.‟‟ [20] Then it began to decline. 
Understanding of the pathogenesis of tuberculosis began with the work of The´ophile Laennec at 
the beginning of the 19th century and was further advanced by the demonstration of the 
transmissibility of Mycobacterium tuberculosis infection by Jean-Antoine Villemin in 1865 and 
the identiﬁcation of the tubercle bacillus as the etiologic agent by Robert Koch in 1882[21] . 
Clemens von Piquet developed the tuberculin skin test in 1907 and 3 years later used it to 
demonstrate latent tuberculosis infection in asymptomatic children. In the late 19th and early 20 
centuries sanatoria developed for the treatment of patients with tuberculosis.
 [22]
 The rest provided 
there was supplemented with pulmonary collapse procedures designed to rest infected parts of 
lungs and to close cavities.
 [23]
 Public Health measures to combat the spread of tuberculosis 
emerged following the discovery of its bacterial cause.
 [24]
 BCG vaccination was widely employed 
following World War I.
 [25]
 the modern era of tuberculosis treatment and control was heralded by 
the discovery of streptomycin.
 [26, 27, 28]
  
TYPES: 
Tuberculosis (TB) may be regarded in two categories: active disease or latent infection. 
The most common form of active TB is lung disease, but it may invade other organs, so called 
"extra pulmonary TB."
 [29]
  
 
Active TB Disease: 
 
Active TB is an illness in which the TB bacteria are rapidly multiplying and invading 
different organs of the body
 [30]
. The typical symptoms of active TB variably include cough, 
phlegm, chest pain, weakness, weight loss, fever, chills and sweating at night
 [31]
. A person with 
active pulmonary TB disease may spread TB to others by airborne transmission of infectious 
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particles coughed into the air.
 [31][32][33]
 Depending on state or local public health regulations, the 
patent may be asked to take  antibiotics under the supervision of a physician or other healthcare 
professional.
 [34]
 This program is called "Directly Observed Therapy" and is designed to prevent 
abandon mentorerratic treatment, which may result in "failure" with continued risk of 
transmission or acquired resistance of the bacteria to the medications, including the in famous 
multidrug resistant TB (MDR-TB).
 [35, 36]
  
 
Miliary TB: 
 
Miliary TB is a rare form of active disease that occurs when TB bacteria find their way 
into the bloodstream.
 [37]
 In this form, the bacteria quickly spread all over the body in tiny nodules 
and affect multiple organs at once. This form of TB can be rapidly fatal.
 [38]
  
 
Latent TB Infection: 
 
Many of those who are infected with TB do not develop overt disease.
 [39]
 They have no 
symptoms and their chest x-ray may be normal
 [40]
. The only manifestation of this encounter may 
be reaction to the tuberculin skin test (TST) or interferon-gamma release assay (IGRA). However, 
there is an on-going risk that the latent infection may escalate to active disease.
 [41]
  increased 
Infection.
 [42]
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MYCOBACTERIA 
Mycobacteria are transition forms between bacteria and fungi.
 [43]
 The genus 
Mycobacterium belongs to the order Actinomycetales and the family mycobacteriaceae it is 
characterized by non-motile, non-sporulation rods that resist decolonization with acidified organic 
solvents and called as “acid fast”. [43, 44]  
Some mycobacterial species are pathogenic for humans among these, M. tuberculosis 
hominies and M. tuberculosis bovis.
[45]
  Another variety M. africanum, endowed with 
characteristics intermediate between those of M. tuberculosis hominies and M. tuberculosis bovis 
is also pathogenic for humans.
 [46]
  
 
                                     Figure1, 2
[45]
 
[46]
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Mycobacterial cell wall:  
The cell wall is a major virulence factor of Mycobacterium tuberculosis and contributes to 
its intrinsic drug resistance.
 [47]
 Recently, cryo-electron microscopy showed that the mycobacterial 
cell wall lipids form an unusual outer membrane.
 [48]
 Identification of the components of the 
uptake and secretion machinery across this membrane is critical for understanding the physiology 
and pathogenicity of Tuberculosis and for the development of better anti-tuberculosis drugs.
 
[49,50]
  Although the genome of Tuberculosis appears to encode over 100 putative outer membrane 
proteins, only a few have been identified and characterized.
 [51]
 Here, we summarize the current 
knowledge on the structure of the mycobacterial outer membrane and its known proteins. Through 
comparison to transport processes in Gram-negative bacteria, we highlight several hypothetical 
outer membrane proteins of Tuberculosis awaiting discovery.
 [52, 53]
  
Figure-3
[52, 53]
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Mycobacteria have a complex cell envelope  
Scientific interest in mycobacteria has been sparked by the medical importance of 
Mycobacterium tuberculosis and by properties that distinguish them from other microorganisms.
 
[54]
 In particular, mycobacteria possess a remarkably complex cell envelope consisting of a 
cytoplasmic membrane and a cell wall, which constitutes an efficient permeability barrier and 
plays a crucial role in the intrinsic drug resistance and in survival under harsh conditions.
 
[55]
 These microbes produce a fascinating diversity of lipids such as the mycolic acids, 
exceptionally long fatty acids that account for 30% to 40% of the cell envelope mass.
 [56]
 Mycolic 
acids are covalently linked to peptidoglycan via an arabino galactan polymer, a polysaccharide 
composed of arabinose and galactose subunits.
 [57]
 In a typical arrangement, the peptidoglycan 
network is substituted by linear galactan molecules, which bear several branched arabinose chains 
these branches end in four arabinose dimers, each forming the head group for two mycolic acid 
molecules.
 [58]
.  
     
 Mycobacterial outer membranes 
In 1982, Minnikin proposed that mycobacteria have a second lipid bilayer formed by an 
inner Leaflet of mycolic acids (covalently bound to the peptidoglycan) and an outer leaflet of free 
Lipids. 
[59]
 This proposal was the basis for a variety of models, suggesting an asymmetric outer 
Membrane-like lipid layer of exceptional thickness (≥10 nm). [60] Although freeze fracture 
Experiments supported the existence of this second membrane , electron microscopy of ultrathin 
sections failed to demonstrate the lipid bilayer structure, which was readily observed for the 
cytoplasmic membrane.
 [61]
 A breakthrough was achieved by the use of cryo-electron tomography 
(CET) and electron microscopy of ultrathin cryosections , techniques that abstain from harsh 
chemical treatment of biological samples CET revealed the native three-dimensional organization 
of the cell envelope of Mycobacterium smegmatis and Mycobacterium bovis BCG and disclosed 
the bilayer structure of the outer membrane.
 [62]
 While the lipopolysaccharide-containing outer 
membrane of Gram-negative bacteria consists of leaflet of different thicknesses electron 
microscopy showed that the mycobacterial outer membrane is approximately 8 nm thick and is 
morphologically symmetrical.
 [63]
 This finding, in combination with the observation that the mild 
detergent octyl β-glucoside permeabilizes the outer membrane of M. smegmatis, suggests that free 
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lipids with heterogeneous head groups are distributed over both leaflets in the mycobacterial outer 
membrane and are not restricted to the outer leaflet alone in contrast to all previous models
 [64]
. 
 The porin pathway across mycobacterial outer membranes 
While hydrophobic compounds can penetrate membranes by temporarily dissolving in the 
lipid bilayer, direct diffusion of water-soluble compounds across any lipid bilayer is too slow to 
support bacterial growth.
 [65]
 Thus, uptake of most hydrophilic solutes across the mycobacterial 
outer membrane likely requires some kind of transport proteins.
 [66]
 A strong argument in favour 
of this hypothesis is provided by the existence of porins such as Mycobacterium smegmatis (MspA) 
in mycobacteria. Porinsare defined as non-specific protein channels in bacterial outer membranes 
which enable the influx of hydrophilic solutes.
 [67]
 MspA was discovered as the major porin and 
the most abundant protein of M. smegmatis .Deletion of MspA reduced the outer membrane 
permeability towards glucose phosphate .metal ions and amino acids indicating that MspA 
represents the major general diffusion pathway in M. smegmatis. The loss of several Msp porins 
reduced the growth rate of M. smegmatis indicating that the influx of hydrophilic nutrients 
through porins are required for normal growth.
 [68]
 The requirement for fast nutrient uptake is 
likely not as stringent for M. tuberculosis, with a generation time of 24 hours compared to 3 hours 
for M. smegmatis. This might be the reason why M. tuberculosis does not have MspA 
homologues.
 [69]
 To assess the role of the porin pathway in M. tuberculosis and M. bovis BCG, the 
mspA gene of M. smegmatis was expressed in these species.
 [70]
 Even a very low number of MspA 
pores increased glucose uptake and accelerated growth of M. bovis BCG. 
[71]
 Further, both M. 
bovis BCG and M. tuberculosis became more susceptible to β-lactam antibiotics, isoniazid, 
ethambutol and streptomycin.
 [72]
 These results indicate that the very low efficiency and/or low 
number of endogenous pores contribute to the slow nutrient uptake and the intrinsic resistance of 
these organisms to drugs.
 [73]
  
 
Nevertheless, pore-forming proteins have been detected in M. tuberculosis and M. bovis 
BCG; further supporting that diffusion across the lipid bilayer of the outer membrane is too slow, 
at least for some solutes.
 [474]
 The C-terminal domain of one of these pore-forming proteins, 
OmpATb (Rv0899), has weak similarity to outer membrane proteins of the OmpA family of 
Gram-negative bacteria. Purified recombinant OmpATb was shown to form channels in lipid 
membranes and uptake of serine (but not of glycine) was reduced in the mutant of M.tuberculosis 
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lacking ompATb. 
[75]
 However, at pH 5.5, a 30-fold increase in transcription of ompATb was 
associated with decreased permeability of M. tuberculosis to serine. 
[76]
 Considering these 
conflicting results, it appears doubtful that the primary function of OmpATbin  M. tuberculosis is 
that of a major porin .Another porin candidate, Rv1698, was identified as an outer membrane 
protein of M.tuberculosis with channel activity. 
[77]
 Heterologous expression of rv1698 in an 
M.smegmatis porin mutant partially complemented the permeability defects of the strain.
 [78]
  
 
 Structure of mycobacterial outer membrane proteins 
MspA is the only mycobacterial protein whose crystal structure has been solved. The 
structure has proven to be of immense value not only as a paradigm for a new class of proteins, 
but also for understanding the function of MspA , for elucidating its membrane topology, and for 
applications in nanotechnology .
 [79]
 The porin has an octameric goblet-like conformation with a 
single central channel 10 nm in length. This structure is different from that of trimetric porins in 
Gram-negative bacteria which have one pore per monomer and are approximately 5 nm long. The 
constriction zone of the octameric MspA channel consists of 16 aspartate residues (D90/D91) 
creating a high density of negative charges, which likely explain the cation preference of this 
porin.
 [80, 81]
  Due to its novel protein architecture, MspA became the founding member of a new 
class of outer membrane proteins which has more than 30 homologues in mycobacteria. More 
high-resolution structures are needed to identify unique characteristics of mycobacterial outer 
membrane proteins as well as features that are shared with proteins of Gram-negative bacteria.
 [82]
  
 
 Energy-dependent uptake of nutrients across outer membranes 
Despite its important role in the uptake of some hydrophilic nutrients, the porin pathway is 
not efficient enough for (i) solutes of very low abundance (below 1 μM), such as iron, because 
small concentration gradients result in very low diffusion rates; and (ii) large solutes such as 
vitamin B12 exceed the size exclusion limit of most porin channels. Hence, uptake of these 
solutes across the outer membrane of Gram-negative bacteria requires active transport.
 [83]
 
Substrates of energy-dependent transport systems bind with high affinity to surface receptors, 
Many with dissociation constants in the sub-Nano molar range.
 [84]
 In E. coli, energy is provided 
By the inner membrane complex ExbBD via the periplasmic protein TonB to multiple outer 
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Membrane receptors.
 [85]
  
Iron is highly limited to bacterial pathogens due to sequestration by the host and, therefore, 
needs to be acquired by active transport
 [86]
. This is achieved by high affinity siderophores which 
are specifically taken up by outer membrane receptor proteins in Gram-negative bacteria .E. coli 
contains three major independent siderophore receptors in the outer membrane: FhuA,FepA and 
FecA.
 [87]
 Upon binding an iron-loaded siderophore, energy transferred by TonB initiates 
structural rearrangements in the transporter, releasing the siderophore into the periplasm where 
substrate binding protein shuttles it to a specific transporter of the ATP-binding cassette 
transporter family in the inner membrane.
 [88]
  
M. tuberculosis produces two salicylate-derivedsiderophores. The more polar 
carboxymycobactin is released into the medium, whereas the less polar mycobactin remains 
associated with the cell.
 [89]
  In this bacterium, an ABCtransporter composed of the proteins IrtA 
and IrtB is required for export of siderophores across the inner membrane .
 [90]
 Uptake of iron-
loaded carboxymycobactin is not energy-dependent, leading to the hypothesis that siderophores 
might diffuse through porins.
 [91]
 
 Uptake of hydrophobic compounds across outer membranes 
Nikaido and co-workers have shown that diffusion rates through the water-filled channels 
ofporins drop drastically with increasing solute hydrophobicity .
 [92]
 Both direct diffusion of 
anionic fatty acids through lipid membranes and alternative „flip-flop‟ movement of protonated 
fatty acids through membrane are slow.
 [93]
 These findings explain why bacteria and eukaryotes 
have evolved proteins for fatty acid uptake across membranes. For example, the outer membrane 
protein FadL mediates energy-independent uptake of fatty acids by E. coli. 
[95]
  
Considerable circumstantial evidence suggests that M. tuberculosis uses lipids as a carbon 
source after the onset of the adaptive immune response in mice. However, no FadL homologue is 
apparent in mycobacteria, and the mechanism by which fatty acids cross the mycobacterial outer 
membrane is unknown.
 [96]
 Identification of an outer membrane fatty-acid transporter will be 
important for understanding the physiology of M. tuberculosis in the human host and might shed 
light on the types of lipids used by this microbe. In addition to fatty acids, cholesterol is another 
hydrophobic compound which appears to be used by M. tuberculosis asa carbon source.
 [97, 
98]
  Interestingly, the mce4 operon is required for efficient uptake of cholesterol and encodes some 
proteins (Mce4A, Mce4B, Mce4C, Mce4D and Mce4F) that have been proposed to be outer 
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membrane proteins, based on secondary structure predictions and other characteristics.
 [99]
 They 
might form an outer membrane channel to enable cholesterol to enter the cell.            
 Efflux processes 
M. tuberculosis is intrinsically resistant to many antibiotics due to the formidable 
permeability barrier established by the outer membrane, in synergy with other resistance 
mechanisms such as multi-drug efflux.
 [100]
 considering that its genome encodes 69 putative drug 
efflux pumps, it is not surprising that all current tuberculosis drugs are substrates of efflux. In 
Gram negative bacteria, only efflux across both membranes is an effective resistance mechanism, 
and we expect a similar situation to occur in mycobacteria
 [101]
. The major drug efflux system of 
E. coli is a tripartite pump consisting of an inner-membrane transporter protein (AcrB), 
aperiplasmic adapter protein (AcrA) and an outer membrane channel (TolC).
 [102]
 E. coli 
tolCmutants are highly susceptible to a wide variety of toxic compounds .Although TolC 
homologues are ubiquitous among Gram-negative bacteria; they do not seem to exist in 
mycobacteria.
 [103]
 hence, we hypothesize that M. tuberculosis might have an outer membrane 
channel protein that connects to inner membrane pumps, allowing for efficient efflux across the 
two membranes.
 [104]
 this hypothesis is supported by the observation that overexpression of 
rv0194, a gene encoding an inner-membrane ABC transporter of Tuberculosis, increased 
resistance of M. bovis BCG to ampicillin.
 [105]
 because targets of β-lactam antibiotics are located in 
the periplasm, increased resistance must result from efflux across the outer membrane.
 [106]
 a 
connection of an outer membrane channel with an inner membrane efflux pump similar to the 
drug efflux systems in Gram-negative bacteria would also provide the energy required for efflux 
against the concentration gradient.
 [107,108]
 Discovery of a TolC-like protein would represent a 
major breakthrough in our understanding of drug efflux in M. tuberculosis
 [109]
.                                 
 Other putative outer membrane protein 
In the previous sections, we have highlighted a few transport processes requiring outer 
membrane proteins.
 [110]
 yet, many other functions as described in Gram-negative bacteria are 
completed by proteins embedded in the outer membrane.
 [111]
 we propose that functionally 
equivalent proteins exist in mycobacteria. For example, yet is required by E. coli to correctly 
insert proteins into the outer membrane.
 [112]
 Conditional depletion of the homologous Omp85 in 
Neisseria gonorrhoeae results in periplasmic accumulation of miss folded proteins.
 
[113]
 Mycobacteria might possess a functional homologue of protein insertion machinery in the 
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outer membrane. Similarly, Gram-negative bacteria require an outer membrane protein, Imp, to 
insert lipopolysaccharide (LPS) into the outer leaflet of the outer membrane.
 [114]
 such membrane 
assembly proteins are likely also required for the many different lipids in the outer leaflet of 
mycobacterial outer membranes.
 [115]
 For example, transport of the phthiocerol di mycocerosates 
(PDIMs) requires the inner membrane transporter MmpL7 and the lipoprotein LppX, but it is 
unknown how PDIMs cross the outer membrane to reach the cell surface.
 [116]
 Mycobacteria 
produce capsules and biofilms, but it is unknown how the materials for these extracellular 
structures are secreted to the cell surface.
 [117]
 In E. coli, capsular material is Trans locating across 
the outer membrane by the Wza protein.
 [118]
 given the requirement of extracellular structures for 
the survival of M. tuberculosis during infection we propose that secretion machinery for biofilm 
and capsular materials in the outer Membrane also exists.
 [119]
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PATHOPHSIOLOGY: 
 When many infectious units of 1-3 bacilli are inhaled, a phenotypically hardy bacillus is 
likely to be among them. In addition, the alveolar macrophages apparently vary in their capacity 
to destroy bacilli.
 [120]
    
Staining for acid-fast bacilli is very useful for demonstrating M. tuberculosis 
 Histologically, tuberculosis displays exudative inflammation 
 proliferative inflammation 
 and productive inflammation[121,122]  
                                      Figure-4
[123]
  
 
Once inhaled, the infectious droplets settle throughout the airways. The majority of 
the bacilli are trapped in the upper parts of the airways where the mucus-secreting goblet 
cells exist.
 [123]
 the mucus produced catches foreign substances, and the cilia on the surface 
of the cells constantly beat the mucus and its entrapped particles upward for removal. This 
system provides the body with an initial physical defense that prevents infection in most 
persons exposed to tuberculosis.
 [124]
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TRANSMISSION:  
 
M. tuberculosis is carried in airborne particles, called droplet nuclei, of 1–5 microns in 
diameter. Infectious droplet nuclei are generated when persons who have pulmonary or laryngeal 
TB disease cough, sneeze, shout, or sing.
 [125]
 Depending on the environment, these tiny particles 
can remain suspended in the air for several hours. M. tuberculosis is transmitted through the air, 
not by surface contact. Transmission occurs when a person inhales droplet nuclei containing M. 
tuberculosis, and the droplet nuclei traverse the mouth or nasal passages, upper respiratory tract, 
and bronchi to reach the alveoli of the lungs.
 [126]
  
         Figure-5
[126]
  
TB is spread from person to person through the air. The dots in the air 
Represent droplet nuclei containing tubercle bacilli. 
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Factors that Determine the Probability of Transmission of M. tuberculosis:
 [127]
  
Table-1 
 
FACTOR DESCRIPTION 
Susceptibility Susceptibility (immune status) of the exposed individual 
Infectiousness Infectiousness of the person with TB disease is directly related to the 
Number of tubercle bacilli that he or she expels into the air. Persons who 
expel many tubercle bacilli are more infectious than patients who expel few 
or no bacilli 
Environment Environmental factors that affect the concentration of M. tuberculosis 
Organisms 
Exposure Proximity, frequency, and duration of exposure 
 
 
 
PATHOGENESIS AND EPIDEMIOLOGY 
Infection occurs when a person inhales droplet nuclei containing tubercle bacilli that reach 
the Alveoli of the lungs. These tubercle bacilli are ingested by alveolar macrophages; the majority 
of these bacilli are destroyed or inhibited.
 [127]
  
 
Tuberculosis is sometimes an acute but more frequently a chronic communicable disease 
that derives its character from several properties of the tubercle bacillus, which in contrast with 
many common bacterial pathogens, multiplies slowly, does not produce exotoxins, and does not 
stimulate an early reaction from the host. The tubercle bacillus is also an intracellular parasite, 
living and multiplying inside macrophages.
 [127]
   
Chronic pulmonary tuberculosis in adults may be due to reactivation of the primary 
infection or to exogenous reinfection. A typical characteristic of tuberculosis is the formation in 
the infected tissue nodular formations called tubercles, which can have different sizes and 
different modes of diffusion, giving rise to various clinical forms called military, infiltrate, lobar 
tuberculosis, and so on. The disease progresses by means of ulceration, caseation and cavitation, 
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with bronchogenic spread of infectious material. Healing may occur at any stage of the disease by 
processes of resolution, fibrosis, and calcification.
 [128]
  
Control of the disease has been achieved in part through mass vaccination with BCG (the 
bacillus of Calmette and Guerin, an attenuated strain of M. tuberculosis bovis). 
DRUG-RESISTANT TB (MDR AND XDR): 
Drug-resistant TB is caused by M. tuberculosis organisms that are resistant to the drugs 
normally used to treat the disease (Figure). Drug-resistant TB is transmitted in the same way as 
drug-susceptible, and is no more infectious than drug-susceptible TB.
 [129]
 however, delay in the 
recognition of drug resistance or prolonged periods of infectiousness may facilitate increased 
transmission and further development of drug resistance.
 [130]
  
                            
                                  
                                                                   Figure-6
[130]
  
                                                      Drug-Resistant Tuberculosis 
GENOME: 
Countless millions of people have died from tuberculosis, a chronic infectious disease 
caused by the tubercle bacillus. The complete genome sequence of the best-characterized strain of 
Mycobacterium tuberculosis, H37Rv, has been determined and analysed in order to improve our 
understanding of the biology of this slow-growing pathogen and to help the conception of new 
prophylactic and therapeutic interventions.
 [131,132]
  The genome comprises 4,411,529 base pairs, 
contains around 4,000 genes, and has a very high guanine + cytosine content that is reflected in 
the biased amino-acid content of the proteins. M. tuberculosis differs radically from other bacteria 
in that a very large portion of its coding capacity is devoted to the production of enzymes involved 
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in lipo genesis and lipolysis, and to two new families of glycine-rich proteins with a repetitive 
structure that may represent a source of antigenic variation.
 [133] 
 Figure-7
[133]
  
 
H37Rv.....GSGAPGGAGGAAGLWGTGGAGGAGGSSAGGGGAGGAGGAGGWLLGDGGAGGIGGAST... 
BCG.......GSGAPGGAGGAAGLWGTGGA----------------GGAGGWLLGDGGAGGIGGAST... 
 This codon‟s of H37RV genome sequence.  
 
CURRENT STATUS OF TUBERCULOSIS: 
Tuberculosis (TB) continues to remain one of the most pressing health problems in India. 
India is the highest TB burden country in the world, accounting for one fifth of the global 
incidence - an estimated 1.96million cases annually. Approximately 2.9million people die from 
tuberculosis each year worldwide; about one fifth of them in India alone .Nearly 500,000 die from 
the disease – more than1000 per day–one every minute. The disease is a major barrier to social 
and economic development.
 [134]
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An estimated 100 million workdays are lost due to illness. The society and the country 
also incur a huge cost due to TB–nearly US$ 3 billion in indirect cost and US$ 300 million in 
direct costs. The situation is more complicated considering that disproportionately affects the 
young population in India. TB mortality in the country has reduced from an estimated 42 per lakh 
population in 1990 to 28 per lakh population in 2006, and the prevalence of TB in the country has 
reduced from 568 per lakh population in 1990 to 283 per lakh population by the year 2012.
 [135]
  
NEW PIPELINE FOR TB DRUG’S SYSTHESIS: [136]  
 
 
THE DRUG DISCOVERY PROCESS
: 
Drug discovery process basically is a patient oriented science, where researchers strive to 
improve the existing drugs or invent a totally new chemical entity, which should be ideally more 
potent than any existing drug of a similar category. If not, then at least it should be safer than those 
existing. This process is a very time consuming and expensive activity, calling for the expertise of 
many eminent researchers. It takes nearly 12-14 years of exhaustive research and a huge amount of 
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financial investment for the discovery of a single drug. Right from the chemical synthesis to its 
clinical development and finally formulating it to a suitable form. Failure at any stage would mean a 
huge loss for the company. Hence, a lot of planning is required even before the project is underway. 
Recently, with the use of technology the process is becoming a less risky business, because of the 
ability of the computers to predict the possible outcomes. This will surely reduce the efforts in fruitless 
directions. [138]                                                                  
 Figure-8
[138]
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TARGET IDENTIFICATION AND VALIDATION: 
Target identification involves choosing the right target which binds with the small 
molecule. A target is generally a single molecule, such as gene or protein, which involved in the 
pathogenesis of a particular disease. The target should be selected in such a way that it could 
potentially interact with and be affected by the drug molecule.
 [139]
  
LEAD IDENTIFICATION: 
Lead identification is the search for the molecule or lead compound that may act on the 
target to alter the disease course. The ways to find a lead compound are as follows: 
De novo: 
De novo design refers to a computer assisted molecular design that supports drug 
discovery by suggesting novel chemo types and compound modifications for lead structure 
optimization.
 [140]
  
High-throughput Screening:  
This process is the most common way that leads are usually found. Advances in robotics 
and computational power allow researchers to test hundreds of thousands of compounds against 
the target to identify any that might be promising. Based on the results, several lead compounds 
are usually selected for further study.
 [141]
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Biotechnology:  
This field involves genetically engineering living systems to produce disease-fighting 
biological molecules.
 [142]
  
LEAD OPTIMIZATION: 
Lead compounds that survive the initial screening are then “optimized,” or altered to make 
them more effective and safer. By changing the structure of a compound, its properties could be 
altered. For example, they can make it less likely to interact with other chemical pathways in the 
body, thus reducing the potential for side effects.
 [143]
  Hundreds of different variations or 
“analogues” of the initial leads are made and tested. Teams of biologists and chemists work 
together closely: The biologists test the effects of analogues on biological systems while the 
chemists take this information to make additional alterations that are then retested by the 
biologists. The resulting compound is the candidate drug.
 [144]
  
New techniques such as magnetic resonance imaging, X-ray crystallography, along with 
powerful computer modeling techniques helps us to visualize the target in three dimensions and 
design potential drugs to more powerfully bind to the parts of the target where they can be most 
effective.
 [145]
  
DRUG DESIGN: 
For the pharmaceutical industry, the number of years to bring a drug from discovery to 
market is approximately 12-14 years and costing up to $1.2 - $1.4 billion dollars. Traditionally, 
drugs were discovered by synthesizing compounds in a time-consuming multi-step processes 
against a battery of in vivo biological screens and further investigating the promising candidates 
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for their pharmacokinetic properties, metabolism and potential toxicity.
 [146]
  Such a development 
process has resulted in high attrition rates with failures attributed to poor pharmacokinetics (39%), 
lack of efficacy (30%), animal toxicity (11%), adverse effects in humans (10%) and various 
commercial and miscellaneous factors. Today, the process of drug discovery has been 
revolutionized with the advent of genomics, proteomics, bioinformatics and efficient technologies 
like, combinatorial chemistry, high throughput screening (HTS), virtual screening, de 
novo design, in vitro, in silico ADMET screening and structure-based drug design.
 [147]
  
There are two major types of drug design.  
1.  LIGAND BASED DRUG DESIGN 
2. STRUCTURE BASED DRUG DESIGN 
 
IN-SILICO DRUG DESIGN: 
In-silico methods can help in identifying drug targets via bioinformatics tools.
 [148]
 they can 
also be used to analyses the target structures for possible binding/active sites, generate candidate 
molecules, check for drug likeness, dock these molecules with the target, rank them according to 
their binding affinities, further optimize the molecules to improve binding characteristics. 
The use of computers and computational methods permeates all aspects of drug discovery 
today and forms the core of structure-based drug design. High Performance computing, data 
management software and internet are facilitating the access of huge amount of data generated 
and transforming the massive complex biological data into a workable knowledge in modern day 
drug discovery process.
 [149]
  The use of complementary, experimental and informatics techniques 
increases the chance of success in many stages of drug discovery process, from the identification 
of novel targets and elucidation of their functions to the discovery and development of lead 
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compounds with desired properties. Computational tools offer the advantage of delivering new 
drug candidates more quickly and at lower cost. Major roles of computation in drug discovery are; 
1. Virtual screening and de novo design 
2. Insilco ADME/Toxicity production 
3. Advanced methods for determining protein ligand binding
 [160]
  
 
LIGAND-BASED RUG DESIGN: 
Ligand based approaches commonly consider two or three dimensional chemistry, shape, 
electrostatic and interaction points (e.g. Pharmacophore modelling) to assess similarity.  
STRUCTURE BASED DRUG DESIGN (SBDD) : 
Structure based design attempts to use the three dimensional (3D) protein structure to 
predict which ligands will bind to the target. Structure-based approaches, of which the best known 
is docking, require a protein structure or homology model as a starting point. SBDD is an iterative 
process, in which macromolecular crystallography has been the predominant technique used to 
elucidate the 3D of drug targets. Although both nucleic acids and proteins are potential drug 
targets, by far the majority of such targets are proteins. Given that many proteins undergo 
considerable conformational change upon ligand binding, it is important to design drugs based on 
the crystallographic structures of protein-ligand complexes.
 [161]
  
Crystallography has been successfully used in the de novo design of drugs, but its most 
important use has been, and will continue to be, in lead optimization .It is important to note that 
what is being optimized is the affinity and specificity of compounds to their drug target.  
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Lead optimization is a multi-step process that can be summarized as follow: 
 Expression and purification of the protein of interest. Crystallisation of the protein in 
the presence of a ligand, which can be a non-hydrolysable substrate or can come from a 
biochemical or a cell-based screen. 
 Ligands can be low affinity compound fragments or scaffold. They are generally a 
collection of basic chemical building blocks, each with a molecular weight of less than 
200 Daltons. If the screen identifies several promising ligands, each with a unique 
scaffold, determine the structures of the drug target with as many of these as possible. 
 One or more ligands have been determined and refined, analysis of each structure will 
reveal sites on the ligand that can be optimized to enhance potency to the drug target. 
This can be accomplished by redesigning the ligand with greater hydrophobic, 
hydrogen-bonding and electrostatic complementary to the molecular target. A high 
affinity lead makes the drug design process simple and intuitive. 
 After the ligands have been designed they should be chemically synthesized. It is 
prudent to synthesis five to ten compounds around the proposed ligand to obtain 
structure-activity relationship (SAR) data. 
 Once the synthesized compounds are purified, they are tested in a relevant biochemical 
or cell-based assay to determine whether or not the design was successful.
 [162,163]
  
 
 
 
 
INTRODUCTION 
 
Department of Pharmaceutical Chemistry  Page 26 
 
CYCLOPROPANE SYNTHASE CmaA2 
The crystal structures of cyclopropane synthase CmaA2 is closely related with root mean 
square deviation (RMSD) between the Ca atoms of the core region of less than 0.7Å  The core 
region which contains a seven stranded b-sheet  which are all parallel apart from b7 which runs 
antiparallel. The α-helices flank each side of the sheet and run in the same N- to C- orientation. 
The two long α-helices lie adjacent to the C- terminal ends of the b-sheet, which encloses 
SAM/SAH cofactor binding site. In cyclopropane synthase the overall polypeptide fold are similar 
to other SAM-Mtases in the protein database, such as catechol-O-methyltransferases and DNA 
methyltransferases.
 [164]
  
Despite the low sequence similarity level to other methyltransferases, the cofactor binding 
sites are conserved in sequence and structure.  
The structure of cyclopropane enzymes is revealed by a tunnel approximately 15Å by 10 
Å wide which extends from the surface of the protein to the cofactor binding site. The tunnel is 
exclusively lined with hydrophobic residues and believed to be the binding site for the acyl 
substrate and is virtually identical in the three enzymes CmaA1, CmaA2 and PcaA. Structure of 
CmaA2 in complex with SAH and the lipid like detergents cetyltrimethylammonium bromide 
(CTAB) or didecyldimethylammonium bromide (DDDMAB) have applied this concept. The 
important interactions between the acyl chain and the protein includes Leu192, Ile169, Phe200, 
Ile195, Leu205, Leu236, Tyr232, Leu278 and Phe273 it reveals that the reactive group may sit in 
the active binding site and the length of the acyl chain which these enzymes may accept apart 
from the interactions of the co-crystal structure with the lipid.
 [165]
  
It is clear that the active binding sites for the three cyclopropane synthase structures are 
similar and the residues that bind the SAM cofactor as well as those which are important in 
catalysis are conserved shows that these enzymes operate through the same reaction mechanism.
18 
While comparing the structures of CmaA2 and PcaA the two enzymes which act at the proximal 
position to produce trans and cis cyclopropane rings respectively and reveals only a minor 
differences between the two structures.
 [167]
  
The cyclopropane synthase CmaA2 and other enzyme are the part of FASII pathway for 
the biosynthesis of mycolic acids in mycobacteria and these enzymes acts on a long acyl chain 
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which linked to acyl carrier protein (AcpM). The mechanism for distal versus proximal substrate 
specificity is based on the differing modes of binding of acyl-AcpM.
  
 
Recent studies shows the cyclopropane synthases of M.tuberculosis is considered as a 
novel class of persistence genes and the need of new inhibitors for the persistent phase of 
tuberculosis infection and the absence of the cyclopropanated lipids in human results 
cyclopropane synthases as an attractive target for the new drug development. Despite the apparent 
non-redundancy of the CmaA2 and other cyclopropane synthases, the similarity of this family of 
enzymes in the mode of binding substrates and in their catalytic mechanism is very clear. This 
makes the prospect of a single drug effectiveness against multiple targets is highly possible, so 
that the chance for the development of drug resistance is less.
 [168]
  
MODIFICATIONS INVOLVING METHYL TRANSFER FROM SAM 
Experiments in which mycobacteria are grown in presence of labeled methionine which 
indicates that the methyl group of methionine may become incorporated directly mycolic acids. 
By the incorporation of either [
14
C-methyl]- methionine or [
3
H-methyl]- methionine in growth 
media and it has been shown that the bridging of methylenes in the cyclopropane ring, the carbon 
of methoxy functionality and the methyl branches adjacent to trans-olefins, methoxy and keto 
moieties which are all derived from methionine presumably through S-adenosyl-L-methionine 
(SAM).
 
Also it long proposed that the meromycolyl cyclopropane groups were derived from the 
double bonds.
 [169]
 The evidence for this idea came with the identification of a gene from 
M.tuberculosis capable of conferring upon M. smegmatis , the ability to produce a large amount of 
cyclopropane containing mycolic acids.
 [170]
 This gene is coined CmaA1 for cyclopropane mycolic 
acid synthase (CMAS) which was found to be 34% identical to the E. coli cyclopropane fatty acid 
synthase (CFAS)
 
 in which the cyclopropane is introduced at the distal position. CmaA1 shows 
strong homology to other SAM-dependent methyl transferases, particularly in the region known 
actually to bind SAM.
 [171]
  
The corresponding protein based on the sequence of CmaA1 is CmaA2 which was shown 
to introduce a cyclopropane ring at the proximal position again by characterization of the purified 
chimeric mycolate obtained following heterologus expression in M. smegmatis. This enzyme will 
cyclopropanate the α-1 but not the α-2 mycolates from M. smegmatis suggesting that the enzyme 
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has a specificity for cis double bonds. However M.tuberculosis produces both cis and Tran‟s 
cyclopropane containing mycolates,
 
yet CmaA1 and CmaA2 produce only cis-cyclopropanes. 
Also this suggests the presences of at least one or more enzyme in M.tuberculosis are capable of 
producing Tran‟s cyclopropanes. The Trans series of cyclopropanes are always accompanied by 
an adjacent methyl branch which suggests that the two equivalents of SAM are involved in their 
formation. The first forms a Tran‟s olefin with an adjacent methyl group and the second to form 
the actual cyclopropane ring.
 [172]
  
 
ADME ANALYSIS 
For a drug to be pharmacologically active and exert the action it should posses 
pharmacokinetic properties like absorption, distribution, metabolism and excretion. In the field of 
drug research and development many drug failures do occur, as they do not undergo these 
properties satisfactorily. This has to be ruled out earlier in the process of drug discovery. Many in-
vitro studies are more frequently used to evaluate ADME properties. Some computational 
methods (in silico tools) have been evolved to investigate the most suitable drug molecules.
 [173]
  
Prediction of ADME related properties
[174]
  
Absorption: 
To investigate this in silico models uses simple parameters like log D (diffusion 
coefficient) and polar surface area are the descriptors foe hydrogen bonding capacity and log 
P(partition co efficient) values should fall under the prescribed values as per the  rule of five, 
which determines the absorption. 
Bioavailability: 
Size and shape of the molecule, lipophilicity and flexibility determines the bioavailability. 
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Metabolism: 
Various in silico approaches are existing in evaluating the metabolism namely QSAR and 
3D QSAR. Apart from those computational chemists have updated the structural details in the 
data bases and tools for predicting metabolism.  
EVALUATION OF INSILICO TOXICITY
[175]
  
Toxicity is one of the major criteria to be considered for a molecule to shine as a 
successful clinical candidate in pharmaceutical research. About 20-40 % of drug failure comes 
under this category. Commercial in silico tools estimates toxicity and provides information by the 
use of QSAR (parameters and descriptors), scientific literatures and to some extent in abstracting 
issues from humans. 
In silico approaches like OSIRIS property explorer predicts the carcinogenicity, 
mutagenicity, teratogenicity, immune toxicology, irritation, sensitization, etc. Newly updated tools 
help in evaluating hepato, neuro and cardio toxicity. 
CHARACTERIZATION 
IR SPECTROSCOPY
 [176]
  
Infrared (IR) spectroscopy is one of the most common spectroscopic techniques used by 
organic chemists. The main goal of IR spectroscopic analysis is to determine the chemical 
functional groups in the sample. Different functional groups absorb characteristic frequencies of 
IR radiation. IR spectroscopy is an important and popular tool for structural elucidation and 
compound identification. 
The possible characteristic bands of the nucleus are 
1. 3300-3540 cm-1 N-H Stretching Vibration 
2. 3670-3230 cm-1 O-H Stretching Vibration 
3. 1690-1630 cm-1 C=N Stretching Vibration 
4. 2975-2840 cm-1 C-H Aliphatic Stretching Vibration 
5. 3100-3000 cm-1 C-H Aromatic Stretching Vibration 
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NMR SPECTROSCOPY
 [177]
  
NMR is the most powerful analytical tool currently available to an organic chemist. NMR 
allows characterization of a very small amount of sample (10mg), and does not destroy the sample 
(non-destructive technique). NMR spectra can provide vast information about a molecule's 
structure and can very often be the only way to prove what the compound really is. Typically 
though, NMR is used in conjunction with other types of spectroscopy and chemical analysis to 
fully confirm a complicated molecule's structure. It involves the interaction of the electromagnetic 
radiation and the hydrogen of the nucleus when placed in an external static magnetic field. 
 
Some basic characteristic peaks of the nucleus 
1. Aromatic and hetero aromatic compounds 6-8.5 δ 
2. Alcoholic hydroxyl protons 1-5.5 δ 
3. Aldehyde protons 9-10 δ 
 
MASS SPECTROSCOPY
 [178]
  
Mass Spectrometry is an analytic technique that utilizes the degree of deflection of charged 
particles by a magnetic field to find the relative masses of molecular ions and fragments. It is a 
powerful method because it provides a great deal of information and can be conducted on tiny 
samples. Mass spectrometry has a number of applications in organic chemistry. They are: 
 Determining molecular mass 
 Finding out the structure of an unknown substance 
 Verifying the identity and purity of a known substance 
 Providing data on isotopic abundance 
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BIOLOGICAL EVALUATION 
Anti-tubercular Activity 
There are various high throughput assays available for screening of new chemical entities 
against tuberculosis. They are: 
 Microplate Alamar Blue Assay 
 BACTEC Assay 
 Luciferous Reporter Phage assay 
 REMA Assay 
 Broth Dilution Assay 
 Middle brook(7H 9,7H 10,7H 11) Agar Dilution Assay 
 
THE ALAMAR BLUE ASSAY 
 
Alamar Blue monitors the reducing environment of the living cell. The active ingredient is 
resazurin (IUPAC name: 7-hydroxy-10-oxidophenoxazin-10-ium-3-one), also known as diazo-
resorcinol, azoresorcin, resazoin, resazurine, which is water-soluble, stable in culture medium, is 
non-toxic and permeable through cell membranes. Continuous monitoring of cells in culture is 
therefore permitted.
 [179]
  
 Growth is measured quantitatively by a visual colour change and the amount of 
fluorescence produced is proportional to the number of the living cells which is determined by 
colorimetric and fluorimetric methods. 
Chemistry
 [180]
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Redox principle   
 
This assay is an indirect colorimetric DST method for determining the MIC of TB drug 
strains of Mycobacterium tuberculosis. The redox indicator Alamar blue monitors the reducing 
environment of the living cell. It turns from blue to pink in the presence of mycobacterial growth. 
As the indicator dye accepts electrons it changes from the blue, oxidized, non fluorescent state to 
the pink, reduced, fluorescent state. The oxidation-reduction potential of Alamar Blue is +380 mV 
fore, can be reduced by NADPH   ( Eo = 320 mV), FADH 
(Eo = 220 mV), FMNH (Eo = 210 mV), NADH (Eo = 320 mV), as well as the cytochromes (Eo = 
290 mV to +80 mV). In addition to mitochondrial reductases, other enzymes (such as the 
diaphorases (EC 1.8.1.4, dihydrolipoamine dehydrogenase), NAD (P) H: quinine oxidoreductase 
(EC 1.6.99.2) and flavin reductase (EC 1.6.99.1) located in the cytoplasm and the mitochondria 
may be able to reduce Alamar Blue.
 [181]
  
ADVANTAGES 
 It has accurate time course measurement. 
 It has high sensitivity and linearity. 
 It involves no cell lysis. 
 It is ideal for use with post measurement functional assay. 
 It is flexible as it can be used with different cell models. 
 It is scalable and can be used with fluorescence and/or absorbance based instrumentation 
platforms. 
 It is nontoxic, non-radioactive and is safe for the user. 
APPLICATIONS: 
 Especially meant for studies on Mycobacterium tuberculosis. 
 Used extensively in cell viability and cytotoxicity studies. [182]  
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HETEROCYCLIC CHEMISTRY 
Heterocyclic structures always are a part in the field of research and development in 
organic chemistry. Millions of heterocyclic structures are found to exist having special properties 
and biological importance. Among various compounds, we have chosen imidazole, a fused 
diazole heterocyclic structure. This ring system is present in important biological building-blocks, 
such as histidine, and the related hormone histamine. Many drugs contain an imidazole ring.
 [183]
  
IMIDAZOLE NUCLEUS:  
Imidazole is a planer five-member heterocyclic ring with 3C and 2N atom and in ring N is 
present in 1st and 3rd positions. The imidazole ring is a constituent of several important natural 
products, including purine, histamine, histidine and nucleic acid. Being a polar and ionisable 
aromatic compound, it improves pharmacokinetic characteristics of lead molecules and thus used 
as a remedy to optimize solubility and bioavailability parameters of proposed poorly soluble lead 
molecules.
 [184]
  Imidazole derivatives have occupied a unique place in the field of medicinal 
chemistry. The incorporation of the imidazole nucleus is an important synthetic strategy in drug 
discovery. The high therapeutic properties of the imidazole related drugs have encouraged the 
medicinal chemists to synthesize a large number of novel chemotherapeutic agents. Imidazole 
drugs have broadened scope in remedying various dispositions in clinical medicines. Numerous 
methods for the synthesis of imidazole and also their various structure reactions offer enormous 
scope in the field of medicinal chemistry.
 [185]
   
                                             1H-Imidazole                              
 
 
 
On the basis of various literature surveys Imidazole derivatives shows various 
pharmacological activities
 [187,188]
  
 
  Anti-tubercular activity[186]  
   Anti-fungal and Anti-bacterial activity  
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  Anti-inflammatory activity and analgesic activity 
  Anti-depressant activity 
  Anti-cancer activity[189]  
  Anti-viral activity  
 Antileishmanial activity 
On view of the importance of the imidazole nucleus. It was decided to design nucleus 
based on the imidazole nucleus. One hundred different molecules with the imidazole scaffold 
were drawn and docked. 
 
  
 
 
     Aim and plan of work 
                                                                Research Envisaged and Plan of Work 
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Research Envisaged and Plan of Work 
                                 Objective of the Present Study 
AIM 
        The literature survey reveals to develop novel and potent cyclopropane mycolic acid 
synthase – 2 (cmaA – 2) inhibitors with anti-tubercular activity. 
OBJECTIVE 
 Identification of the common Pharmacophore responsible for the inhibition of cmaA – 2 
using Hiphop module of Catalyst
®
 software 4.11 from Accelrys. 
 Using scaffold hopping technique, generation of 10,000 scaffolds from the drug. 
 Prediction of anti-tubercular activity for the designed using the Hypo refine model and 
to identify novel and potent cmaA – 2 inhibitor using Lipinski rule of five. 
 The potent cmaA – 2 inhibitors attained as results can be used as lead for drug 
development. 
 Docking of the lead with various derivatives using Glide software to the target 1KPI. 
 The derivatives of the compounds from the lead molecule which has higher Glide score 
value were synthesized. 
 Synthesis and characterization 
 
 Synthesis of substituted imidazole. 
 Synthesis of title compounds 
 Study of physical properties of the synthesized compounds 
 Melting point, Percentage yield. 
 TLC profile. 
 Solubility. 
                                                                Research Envisaged and Plan of Work 
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 Spectral studies 
                        The chemical structures of the synthesized compounds were 
characterized by means of IR, 
1
H-NMR, 
13
C-NMR and MASS spectral analysis. 
 
. 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHEMICAL AND 
TOXICITY FILTERS  
CYCLOPROPANE MYCOLIC ACID SYNTHASE (cmaA – 2) 
TARGET FROM MEDICINAL CHEMISTRY JOURNALS  
PRIORITY GIVEN BASED ON 
SYNTHETIC FEASIBILITY AND 
CHEMICAL AVAILABILITY  
SYNTHESIS  
12 HITS OF 
DIFFERENT 
ANALOGUES  
LIPINSKI RULE OF FIVE  
PHARMACOPHORE  
GLIDE 
PDB: 1KPI  
 
FRAGMENT AND 
KNOWLEDGE BASED 
DRUG DESIGN DOCKING  
The present study carried out based on the below flow 
chart 
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List of compounds to be synthesized 
ENTRY COMPOUNDS IUPAC 
 
SU1 
N
N
O
N
+
O
-
O
NH
N
+
O
-
O
N
+
O
-
O  
N-(2,4-dinitrophenyl)-2-(5-
nitrofuran-2-yl)-1H-imidazol-1-
amine 
 
 
SU2 
N
N
NH
N
+
O
-
O
N
+
O
-
O
N
CH3
CH3
 
2-[4-(dimethylamino)phenyl]-N-
(2,4-dinitrophenyl)-1H-imidazol-
1-amine 
 
 
SU3 
S
N
N
N
OH
 
4-[1-(1,3-benzothiazol-2-yl)-1H-
imidazol-2-yl]phenol 
. 
 
SU4 
N
N
O
N
CH3Br
CH3
CH3
 
5-bromo-4-[2-(4-methoxy-3-
methylphenyl)-1H-imidazol-1-yl]-
2-methylpyridine 
. 
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SU5 
N
N
NH
N
+
O
-
O
N
+
O
-
O  
2-cyclohexyl-N-(2,4-
dinitrophenyl)-1H-imidazol-1-
amine 
. 
 
SU6 
N
N
SH
N
CH3
CH3
                
4-{2-[4-
(dimethylamino)phenyl]-
1H-imidazol-1-
yl}benzenethiol 
. 
 
SU7 
N
N
N
CH3
CH3
 
N,N-dimethyl-4-[1-
(naphthalen-1-yl)-1H-
imidazol-2-yl]aniline 
. 
 
SU8 
ON
N
N
N
CH3
CH3
 
N-{2-[4-
(dimethylamino)phenyl]-
1H-imidazol-1-yl}pyridine-
4-carboxamide 
. 
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SU9 
N
N
NH
N
+
O
-
O
N
+
O
-
O
O
CH3
OH
 
5-{1-[(2,4-
dinitrophenyl)amino]-1H-
imidazol-2-yl}-2-
methoxyphenol 
 
 
SU10 
N
N
N
+
O
-
O
 
1-(anthracen-9-yl)-2-(2-
nitrophenyl)-1H-imidazole 
. 
 
SU11 
SN
N
N
S
 
2-[2-(thiophen-2-yl)-1H-
imidazol-1-yl]-1,3-
benzothiazole 
. 
   
SU12 
N
N
S
N
Br
CH3
 
2-bromo-5-methyl-4-[2-
(thiophen-2-yl)-1H-imidazol-
1-yl]pyridine 
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1. Rahul Jain et al.,(2005) Tuberculosis (TB) is one of the most devastating diseases 
primarily due to several decades of neglect,and presents a global health threat of escalating 
proportions. TB is the second leading infectious causes ofmortality today behind only 
HIV/AIDS. 
 
2. George KM,et al.,(2008) The biosynthesis of cyclopropanated mycolic acids in 
Mycobacterium tuberculosis. Identification and functional analysis of CMAS-2 revealed the 
gene whose product cyclopropanates the proximal double bond was cloned by homology to a 
putative cyclopropane synthase identified from the Mycobacterium leprae genome 
sequencing project. This gene, named cma2, was sequenced and found to be 52% identical to 
cma1 (which cyclopropanates the distal double bond) and 73% identical to the gene from M. 
leprae. Both cma genes were found to be restricted in distribution to pathogenic species of 
mycobacteria. Expression of cma2 in Mycobacterium smegmatis resulted in the 
cyclopropanation of the proximal double bond in the alpha 1 series of mycolic acids. 
 
3 .Dominique Guianvarc'h,et al.,(2009) Identification of inhibitors of the E. coli 
cyclopropane fatty acid synthase from the screening of a chemical library: revealed an in 
vitro and in vivo studies, using an automated coupled colorimetric assay for the Escherichia 
coli cyclopropane fatty acid synthase (CFAS). 
 
4. Christine et al.(2007), Synthesis and evaluation of analogues of S-adenosyl-L-methionine, 
as inhibitors of the E. coli cyclopropane fatty acid synthase. They synthesised some 
analogues of S-adenosyl-l-methionine were synthesized and evaluated as inhibitors of the 
purified E. coli cyclopropane fatty acid synthase, a model for M. tuberculosis cyclopropane 
synthases that are potential targets for antituberculous drugs. 
 
5. Cécile Asselineau et al.(2003), reviewed the biosynthesis of mycolic acids by 
mycobacteria: current and alternative hypotheses by adding the classical elongation process 
of fatty acid synthesis produces two long chains, the condensation of which leads to the direct 
precursors of mycolic acids.  
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6. Michael S. Glickman et al.,(2012) revealed that Mycobacterium tuberculosis lacking all 
mycolic acid cyclopropanation is viable but highly attenuated and hyper inflammatory in 
mice. 
 
7. James C. Sacchettini et al.,(2004) worked on TB drug discovery: addressing issues of 
persistence and resistance by reviewing the recent developments of some of the pathways 
involved in a persistent infection and pathogenesis of mycobacterium tuberculosis, which 
reveal new targets for drug development. 
 
8. Liao RZ et al,(1978) Mechanism of mycolic acid cyclopropane synthase: a theoretical 
study. They demonstrated that the reaction starts via the transfer of a methyl to the substrate 
double bond, followed by the transfer of a proton from the methyl cation to the bicarbonate 
present in the active site. 
 
9. Chih-chin Huang et al.(2012), Mycolic acids are major components of the cell wall of 
Mycobacterium tuberculosis. Several studies indicate that functional groups in the acyl chain 
of mycolic acids are important for pathogenesis and persistence. There are at least three 
mycolic acid cyclopropane synthases (PcaA, CmaA1, and CmaA2) that areresponsible for 
these site-specific modifications of mycolic acids. 
 
10. Romano T. Kroemeret et al.(2003), this review gives an introduction into ligand – 
receptor docking and illustrates the basic underlying concepts. An overview of different 
approaches and algorithms are provided. Although the application of docking and scoring has 
led to some remarkable successes, there are still some major challenges ahead, which are 
outlined here as well. Approaches to address some of these challenges and the latest 
developments in the area are presented. 
 
11.Thomas Hughes,et al.(2009), It is the mission of pharmaceutical research companies to 
take the path from understanding a disease to bringing a safe and effective new treatment to 
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patients. Scientists work to piece together the basiccauses of disease at the level of genes, 
proteins and cells. 
12. Andrew Worth et al.(1998), Distribution, Metabolism and Excretion (ADME) 
properties, which are often important in discriminating between the toxicological profiles of 
parent compounds and their metabolites/degradation products. The review was performed in 
a broad sense, with emphasis on QSARs and rule-based approaches and their applicability to 
estimation of    oral bioavailability, human intestinal absorption, blood-brain barrier 
penetration, plasma protein 
binding, metabolism and. This revealed a vast and rapidly growing literature and a range of 
software tools. 
 
13. Shafiee A.et al.,(2008) Synthesis and antitubercular activity of new N,N-diaryl-4-(4,5-
dichloroimidazole-2-yl)-1,4-dihydro2,6dimethyl3,5pyridinedicarboxamides.Dihydropyridines 
having carboxamides in 3 and 5 positions show anti-tuberculosis activity. The purpose of the 
present study was tosynthesize new DHPs having possible anti-tuberculosis activity. 
 
 
 
14.Thompson,et al.,(1995) Synthesis, Reduction Potentials, and Antitubercular Activity of 
Ring A/B Analogues of the Bioreductive Drug (6S)-2-Nitro-6-{[4-
(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5H-imidazo[2,1b][1,3]oxazine (PA-824) 
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15. Rawat M.S.M.et al.,(2005) The 5-nitroimidazole is an important class of imidazole 
based drugs. The 5-nitroimidazoles are a well-established group of protozoal and 
bactericidal agents but after discovery of imidazole drugs many protozoa and bacteria has 
developed resistance towards drugs in market. 
 
 
 
16. Daniele Zampieriet et al.(2003), Synthesis, antifungal and antimycobacterial activities of 
new bisimidazolederivatives. 
                                              
17. Elena Banfi et al.,(1998) Antifungal and antimycobacterial activity of new imidazole and 
triazole derivatives. A combined experimental andcomputational approach. 
                                           
                                           
 
 
18.Rama P. Tripathi et al.,(2013) A series of imidazole based compounds were synthesized 
by reacting simple imidazoles with alkyl halides or alkyl halocarboxylate in presence of 
tetrabutylammonium bromide (TBAB). The compounds bearing carbethoxy group undergo 
amidation with different amines in the presence of DBU to give respective carboxamides. 
The synthesized compounds were screened against Mycobacterium tuberculosis where 
compound 17 exhibited very good in vitro antitubercular activity and may serve as a lead for 
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further optimization. 
           
                        
 
19. Prabh Simran Singh et al.,(2012) study of imidazole derivatives to identify them 
asmycobacterium tuberculosis 14dm inhibitors. 
                                                 
 
20. Prasanthy G et al., (2006 a new series of 1-substituted imidazole derivatives were 
synthesized taking different anilines and sulfonamides as substitutions. The chemical 
structures were confirmed by means of IR, 1H-NMR and Mass spectral data. The compounds 
were screened for their anticancer and antimicrobial activities. N-(3-chloro-4-fluorophenyl)-
4-(1H-imidazol-1-yl)benzamide exhibited highest activity against cervical cancer. 4-(1H-
imidazol-1-yl)-N-(4-(N-(5-methylisoxazol-4-yl) sulfamoyl) phenyl) benzamide showed good 
antifungal activity. 4-(1H-imidazol-1-yl)-N-(4-(N-thiazol-4-ylsulfamoyl) phenyl) benzamide 
showed good antibacterial activity. 
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21.Eufrânio N. da Silva Jr. et al.,(2007) synthesis of aryl substituted imidazoles and 
oxazoles and their potent activity against mycobacteriumtuberculosis. 
                                                                
22.Gupta P,et  al.,(2001) We describe in vitro anti-Mycobacterium tuberculosis activities of 
ring-substituted-1H-imidazole-4- carboxylic acid derivatives (1-6), and 3-(2-alkyl-1H-
imidazol-4-yl)-propionic acid derivatives (7-13)against drug-sensitive and drug-resistant M. 
tuberculosis H37Rv strains. 
 
23.Johan Gising et al.(2008), Trisubstituted Imidazoles as Mycobacterium tuberculosis 
Glutamine Synthetase Inhibitors. 
 
                     
 
 
24.Flavia M. da Silva et al.,(1988) a new, simple and eco-friendly protocol has been 
developed for the preparation of trisubstituted imidazoles through the radziszewski reaction 
between formaldehyde (37%aqueous solution), amines, ammonium carbonate and biacetyl.       
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 25. Harsha Tripathy et al.(2003), The reactants, 0.210g (1 millimole) of benzil, 0.076g(1 
millimole) of ammonium acetate, 0.050g(1 millimole) of paraformaldehyde, 2-3 drops of 
80% formic acid and 2 millimoles of amine were taken in 1 mL dry DMF in a long necked 
glass vial. The reaction mixture was irradiated in synthetic microwave oven (Emry’s 
optimizer). The reaction conditions were optimized in Emry’s optimizer as Irradiation time: 8 
minutes, Temperature: 120 °C, Pre-stirring time: 60 seconds, Absorption: Normal, Pressure: 
19 bars.  
                    
 
       
26. Reza Tayebee et al.,(1985) The new results concerning synthesis of some 2,4,5-triaryl-
1H-imidazoles in the absence of any additive, as catalyst, is presented. Moreover, we 
modified the experimental route for the isolation and purification of the un-reacted benzyl, as 
initial reactant, from products at the end of the reaction. 
                                  
 
 27.AL. Abodi et al.,(1988) New 1,3-oxazol-5(4H)-one (3a – b) was synthesized by 
cyclization of[(Pyridyl-3-yl-carbonyl)amino]acetic acid (2). The starting were readily 
obtained by acylation of 2-amino acetic acid (Glycine) with nicotinoyl chloride. Imidazole 
was synthesized by reaction of compounds (3a - b) with hydrazine hydrate (99%). 
Compounds (4a - b) were converted into a variety of derivatives. All new compounds were 
characterized by 1H NMR and FTIR spectroscopy. 
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28.Rajendra P. Pawar et al.(2010), An efficient and green procedure for the synthesis of 2, 
4, 6-triaryl-1H-imidazole in polyethylene glycol under microwave irradiation in excellent 
yield has been developed. Polyethylene glycol is non toxic, reusable, inexpensive andeasily 
available. 
                   
 
29. Sidhanath V. Bhosale et al.,(2007) A series of 2,4,5-triaryl-1H-imidazole was 
synthesized in one step. We demonstrated an efficient protocol for the synthesis of substituted 
imidazole from benzil/benzoin, aldehydes and ammonium acetate without catalyst in 
polyethylene glycol. Product isolation via filtration without any hazardous organic solvent 
claims an environmentally benign protocol for the synthesis of substituted imidazoles. 
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   30.  ASIF HUSAIN et al.,(2005) Disubstituted imidazoles were prepared by reacting 
appropriate phenylglyoxal with different aryl aldehydes in the presence of ammonium 
acetate. Trisubstituted imidazoles were prepared by reacting disubstituted imidazoles with 
chlorobenzene in the presence of catalytic amount of triethylamine (TEA). The synthesized 
compounds were characterized on the basis of IR, 1H-NMR and mass spectral data and 
elemental analysis results. They were tested for their antiinflammatory and antimicrobial 
actions.       
                                              
31.ALI MOHAMMADI et al.,92003) An efficient synthesis of 2,4,5-trisubstituted 
imidazoles is achieved by three component cyclocondensation of benzil or benzoin, aldehyde 
and ammonium acetate by using novel polymeric catalyst [poly(AMPS-co-AA)] under 
solvent-free conditions. The key advantages of this process are high yields, shorter reaction 
times, easy work-up, purification of products by non-chromatographic method and the 
reusability of the catalyst. 
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32. Jadwiga Handzlik et al.,(2001) The paper focuses on recent achievements in the search 
for new chemical compounds able to inhibit multidrug resistance (MDR) mechanisms in 
Gram-positive pathogens. An analysis of the results of the search for new efflux pump 
inhibitors (EPIs) for Gram-positive bacteria, which have been performed over the last decade, 
indicates that almost all efforts are focused on the NorA (MFS) efflux pump in S. aureus 
 
33.Murlidhar S. Shingare et al.,(1997) Boric acid (BO3H3) is an inexpensive, efficient and 
mild catalyst for the synthesis of 2,4,5-triaryl-1H-imidazoles in excellent yields from the one-
pot three-component condensation of benzil/benzoin, an aldehydes and ammonium acetate in 
aqueous media under ultrasound at room temperature. The remarkable advantages offered by 
this method are green catalyst, mild reaction conditions, simple procedures, much faster 
reactions and excellent yield of products. 
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34.Santosh Kumar Singh et al.,(1999) A convenient and practical synthesis of imidazol-1-
yl-acetic acid hydrochloride was achieved via N-alkylation of imidazole using tert-butyl 
chloroacetate followed by a non-aqueous ester cleavage of the resulting imidazol-1-yl-acetic 
acid tert-butyl ester in the presence of titanium tetrachloride. The synthesized imidazol-1-yl-
acetic acid hydrochloride was then utilized to prepare zoledronic acid. 
                                                                             
 
 
35. Qasim et al.,(2009)synthesized 2- phenylimidazo [4,5-f] [1,10] Phenanthroline 
derivatives (42), by reacting dicarbonyl compound (40) and p-substituted benzaldehyde (41), 
this is a type of acid catalyzed reaction with excellent yields in a neutral ionic liquid, 1-
methyl-3-heptylimidazolium tetrafluoroborate [(HeMIM) BF4], under solvent free and 
microwave assisted conditions. This particular reaction accompanies all the merits of 
microwave reactions like easy workup, better yield, and environment friendly reaction 
      
 
36.Ermolat et al.,(2006) synthesized mono and disubstituted-2-amino-1H imidazoles  via 
microwave assisted hydrazinolysis of substituted imidazo [1, 2 a] pyrimidines  is 
reported.This method avoids strong acidic conditions and is superior to the conventional 
cyclocondensation of a haloketones with N-acetyl guanidine. 
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37. Bharadwaj et al .,(2010) performed the condensation of different oxazolones (1a-f) (51) 
with 5- (4-nitrophenyl)-1, 3, 4-thiadiazol-2-amin under microwave oven. The structures of 
the synthesized compounds , 3a-3j were confirmed on the basis of spectral and elemental 
analysis. The synthesised compounds were found in better yield than in conventional 
methods and also screened for in vitro antimicrobial study. 
 
38.Marek et al (2007) synthesized via a facile 4-step reaction sequence starting from 
commercially available and inexpensive N-Cbz amino acids . The condensation of the 
corresponding α bromoketones with formamidine acetate in liquid ammonia was revealed to 
be a useful method for the synthesis of such imidazole derivatives , derivatives thus prepared 
are structurallyrelatedto histamine. 
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39. Safari et al .,(1989) (NH4)6.Mo.7O2. 4H2O was used as an efficient catalyst for an 
improved and rapid synthesis of 2,4,5-trisubstituted imidazoles by a three-component, one-
pot condensation of benzil , aryl aldehydes  and ammonium acetate  in good yields under 
solvent-free conditions using microwave irradiation. The reactions in conventional 
heatingconditions were compared with the microwave-assisted reactions. 
           
 
40. Kamila et al.,(2003) 2-(Alkyl-1-yl)-1H-imidazol-5(4H)-ones  were synthesized via 
nucleophilic substitution of the methylsulfanyl group of the corresponding 2-(methylthio)-
1Himidazol- 5(4H)-ones 3a–c  with suitably substituted secondary amines . The starting 2-
thioxo- imidazolidin-4-ones 2a, 2b were prepared by condensation of thiohydantoin and 
benzo[b]- thiophene-3-carbaldehyde or benzofuran-3-carbaldehyde under microwave 
irradiation (MW) conditions. 2-Methylthio derivatives 3a–c were prepared by treatment of 
2a–b with methyl iodide in the presence of aqueous sodium hydroxide 
            
 
41.Nalage et al .,(2012)described an efficient and green procedure for the synthesis of 2, 4, 6-
triaryl- 1H-imidazole in polyethylene glycol by condensing benzil and 3-methoxy- 4- 
hydroxyl benzaldehyde under microwave irradiation in excellent yield has been 
developed.Polyethylene glycol is non toxic, reusable, inexpensive and easily available. 
 
. 
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42.A.P. Rajput et al.,(2001) 1H-Derivatives of azoles like imidazole-1-acetic acid, 
benzimidazole-1-acetic acid [1-2] benzotriazole-1-acetic acid [3-4], piperazine-1-acetic acid 
have received very little attention. Literature survey finds very little information about these 
compounds. Interest in these azole containing structure stem.
 
43.Abbas SHAFIEE et al.(2012) 4(5)-Chloro-imidazole-5(4)-carboxaldehyde derivatives are 
important precursors for the preparation of biologically active compounds. We developed a 
simple, novel, and efficient method for the synthesis of these compounds. The chemistry 
described is amenable to large-scale use and is flexible enough to allow the preparation of 
analogs. 
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44. Abdul Jabar Kh. Atia et al.,(1996) Metronidazole (MTZ, 1) is a synthetic compound 
used in the treatment of infections caused by Gram negative anaerobic bacteria like 
Helicobacter pylori and protozoa such as Giardia, Lamblia, and Entomoeba histolytica,  
Imidazole and its derivatives are of great significance due to their important roles in 
biological systems, particularly in enzymes, as proton donors and/or acceptors, coordination 
system ligands and the base of charge–transfer processes. 
                                                                
45. Maria Grazia Mamolo et al., 2009 new bis-imidazole derivatives have been synthesized 
and their antifungal and antimycobacterial activity was determined.Almost all compounds 
exhibited a moderate to good activity against two clinical isolates of Candida albicans 3038 
and Candida glabrata123. The same compounds showed an interesting killing activity against 
Mycobacterium tuberculosis H37Rv reference strain. 
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DOCKING STUDIES (GLIDE) 
DOCKING AND SCORING METHODS:   
Docking procedure aims to identify the correct binding poses within the binding site of 
the protein while the scoring function aims to predict binding affinity of ligand for the protein 
binding region
 [190]
. The scoring function serves three purposes. 
1. For ranking the conformations generated by the docking, search for one ligand 
interacting with a given protein, this aspect is essential to detect the best binding site 
mode. 
2. For ranking different ligands with respect to binding to one protein i.e. prioritizing 
ligands according to their affinity, this aspect is essential in virtual screening. 
3. For ranking one or different ligands with respect to their binding affinity to different 
proteins their aspect is essential for the consideration of specificity and selectivity. 
STEPS IN DOCKING: 
PROTEIN PREPARATION
 [191,192,193]
  
A typical PDB file downloaded from protein data bank consists of heavy metals, can 
contain waters, cofactors, metal ions and can be dimeric or multimeric. The structure 
generally has no information on bond orders, topologies, or formal atomic charges. The 
Terminal groups can also be misaligned because the X-ray structure analysis cannot easily 
distinguish between O and NH2 ion. The ionization and tautomeric states are usually 
unassigned. Generally Glide calculations use an all atom force-field for accurate energy 
evaluation and thus, Glide requires bond orders and ionization states which to be properly 
assigned and should performs better when side chains are reoriented, when necessary and 
steric clashes are relieved. 
The steps for the protein preparation carried out are as follows: 
1. The ligand/protein co-crystallized structure of CmaA-2 target (1KPI) in the form of 
PDB was imported into maestro. The preparation component of a protein preparation 
facility requires an identified ligand which to be verified. 
2. The protein-ligand complex is then identified for its form as dimer or other multimer, 
containing duplicate binding sites, and other duplicate chains that are redundant. Then 
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remove the redundant binding sites and the associated chains by picking and deleting 
molecules or chains. 
3. The waters to be identified that bridge between the ligand and protein are retained and 
all the other waters (except those coordinated to metals) are deleted and if waters are 
added then hydrogen can be automatically added and then the orientations of water 
molecules are checked once again. 
4. The protein, metal ions and cofactors are then adjusted. The structures that are 
missing residues near the active sites should be repaired. The covalent bonds from the 
metal ions to the protein should be changed to zero-order bonds. The formal charges 
on the metal and the ligating groups should be adjusted to their appropriate values.  
5. The ligand bond orders and the formal charges are adjusted. In Glide models such 
interactions are associated with vanderwaals and electrostatic interactions. 
6. The restrained minimization of protein structure reorients the side chain containing 
hydroxyl groups and alleviates the potential steric clashes. The minimization is 
restrained to the input protein coordinates by a user-selected RMSD tolerance. 
Figure-9
[191]
  
             5(e)     Crystal structure of Cyclopropane mycolic acid synthase – 2 enzymes: 1KPI 
 
LIGAND PREPARATION
 [194,195]
  
The ligand preparation is designed to prepare a high quality, 3D structures for a large 
numbers of drugs like molecules. The structures which to be docked must have actual ligand 
structures and should meet the following conditions: 
1. The structures must be in three dimensional. 
2. The structures must have realistic bond lengths and bond angles. 
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3. Each structure must consist of a single molecule that has no covalent bonds to the 
receptor, with not accompanying fragments such as counter ions and solvent molecules. 
4. All structures must have their hydrogens. 
5. The structures must have an appropriate protonation state for the physiological pH 
values (around 7). 
     
The LigPrep process consists of a series of steps which perform conversions, 
eliminate unwanted structures, apply corrections to the structures, and optimize the structures. 
The simple use of LigPrep produces a single low-energy 3D structure with correct chiralities 
for every successfully processed input structure. The LigPrep can also produce a large 
number of structures from each input structure with various ionization states, 
stereochemistries, and ring conformations, tautomers, and eliminate molecules using various 
criteria including molecular weight, specified numbers and types of functional groups which 
are present. 
 
RECEPTOR GRID GENERATION
 [196]
  
The grid in which the shape and properties of the receptor are represented by a several 
different sets of fields which provide progressively more accurate scoring of the ligand poses. 
Grids must be prepared for each conformation to ensure that possible actives are not missed 
for receptors that adopt more than one conformation on binding. 
Receptor grid defines the receptor structure by excluding any co-crystallised ligand 
which might be present, determine the position and the size of active site as it will be 
represented by receptor grids, set up the glide constraints, and set up the flexible hydroxyl 
groups. 
The receptor grid generation requires a prepared structure where an all-atom structure 
with appropriate bond orders and formal charges. 
 
LIGAND DOCKING
 [197]
  
Glide ligand docking job requires a set of previously calculated receptor grids and one 
or more ligand structures. The ligand structures must satisfy the criteria listed above in the 
ligand preparation. The detailed information on setting up grid generation job is given above. 
The preparation of ligands before docking is strongly recommended. The LigPrep or Macro 
model in Maestro can be used to prepare ligands. If a correct Lewis structure cannot be 
generated for a ligand, it is skipped by the docking job. 
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DOCKING OF CmaA-2
[198,199,200]
  
Crystal structure of CmaA2 (PDB code-1KPI) was used for the study. The 3D structures 
was downloaded from the Protein Data Bank (PDB) and imported to the Maestro
®
 workflow. 
Hydrogen atoms were added to the proteins and further the force field and other minimization 
was performed using protein preparation wizard. The structure based docking studies of 
CmaA2 inhibitors were carried out using Glide software to the 3D structure of CmaA2 and 
generated 10 best docking poses. During the docking studies, Glide initially performs a 
complete systematic search of conformations, orientations, and the position of a compound in 
the defined active binding site and eliminates the unwanted poses using scoring and energy 
optimization. The best poses were selected based upon the scoring functions and the quality 
of pose orientation within the active binding site amino acids. The molecules selected for the 
synthesis were examined from this docking score which is having a high dock value. 
                       
Figure-10
[198]
       Figure-11
[200]
  
          Docked molecule in the cocrystal of CmaA2 receptor in ribbon form 
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COCRYSTAL AND DOCKING
 [201]
  
Co-crystal and docking were the conformational comparison of these two ligands 
having similar binding modes at the CmaA2 binding site. 
 Crystal structure of CmaA2 (Pdb code: 1KPI) was downloaded from the Protein data 
bank into the maestro workflow. The protein was then split by molecule and generates the co-
crystal. The co-crystal alone was subjected to LigPrep. The output file was further docked 
and then generates docked conformations.  
                               
                                     Figure-12       Co-crystal and docked orientation 
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INTERACTIONS 
The binding modes of compounds SU03, SU 04, SU 05, SU 06,SU 07,SU 08,SU 
09,SU 10,SU 11,and SU 12 in the active site of CmaA2. Carbon atoms of the protein and the 
ligand are indicated in gray. Each dotted line indicates a hydrogen bond. 
 
 
 
SU-1 
SU-2 
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SU-3 
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SU-5 
SU-6 
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SU-7 
SU-8 
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SU-10 
                                                                                      Materials and Methods 
 
Department Of Pharmaceutical Chemistry Page 65 
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INTERACTION BETWEEN PROTEIN AND LIGAND 
 
 Interaction between protein and ligand su-1 
 Interaction between protein and ligand su-2 
 Interaction between protein and ligand su-3 
 Interaction between protein and ligand su-4 
 Interaction between protein and ligand su-5 
 Interaction between protein and ligand su-6 
 Interaction between protein and ligand su-7 
 Interaction between protein and ligand su-8 
 Interaction between protein and ligand su-9 
 Interaction between protein and ligand su-10 
 Interaction between protein and ligand su-11 
 Interaction between protein and ligand su-12 
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XP DOCKING OF MOLECULES GOING TO BE SYNTHESIZED [202]  
Docking of selected molecules from the scaffhold is done by XP mode against 1kpi 
for evaluating the degree of binding by checking or evaluates the following parameters for 
detailed study with the receptor. 
Table-3 
S.NO XP Term Description 
1 GScore 
 
Total GlideScore; sum of XP 
Terms 
2 LipophilicEvdW Lipophilic term derived from 
hydrophobic grid potential and fraction of the total protein 
ligandvdW energy 
3 PhobEn Hydrophobic enclosure reward 
4 PhobEnHB Reward for hydrophobically 
packed H-bond 
5 PhobEnPairHB Reward for hydrophobically 
packed correlated H-bonds 
6 HBond ChemScore H-bond pair term 
7 Electro Electrostatic rewards 
8 SiteMap SiteMap ligand/receptor non-Hbonding polar/hydrophobic 
and hydrophobic/hydrophilic complementarity 
Terms 
9 LowMW Reward for ligands with low 
molecular weight 
10 Penalties Polar atom burial and desolvation penalties, and penalty 
for intra-ligand contacts 
11 HBPenal Penalty for ligands with large 
hydrophobic contacts and low H-bond scores 
12 PhobicPenal Penalty for exposed hydrophobic 
ligand groups 
13 RotPenal Rotatable bond penalty 
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DOCKING SCORE-Table-4 
 
 
 
 
 
Ligand G 
Score 
Lipophilic 
Evdw 
PhobEn PhobEn 
HB 
PhobEn 
PairHB 
H 
bond 
Elect Site 
map 
Pi 
Cat 
ClBr Low 
Mw 
1 -8.0 -3.71 -1.22 -1.5 0 -1.36 -0.82 -
0.03 
0 0 -0.19 
2 -10.0 -3.97 -1.55 0 0 -0.9 -0.11 -0.4 0 0 -0.38 
3 -9.1 -4.08 -1.7 0 0 -0.35 -0.13 -
0.26 
0 0 -0.13 
4 -6.04 -4.67 -1.20 0 0 0 -0.23 -
0.31 
0 0 -0.19 
5 -6.8 -3.75 -1.57 0 0 0 -0.06 -
0.21 
0 0 -0.33 
     6 -5.9 -4.01 -1.2 0 0 -0.7 -
1.84 
-0.3 0 0 -0.5 
7 -6.3 -4.68 -1.35 0 0 -0.7 -
0.09 
-0.3 0 0 -
0.34 
8 -7.4 -4.20 -1.3 0 0 -
0.45 
-
0.06 
-0.1 0 0 -0.5 
9 -8.2 -3.92 -1.2 0 0 -0.7 -
0.43 
-0.5 0 0 -
0.52 
10 -7.6 -4.01 -1.25 0 0 0 -1.5 -0.9 0 0 -0.24 
11 -8.6 -3.52 -1.5 0 0 -0.5 -1.2 -
0.68 
0 0 -0.51 
12 -9.5 -3.68 -1.7 0 0 -0.1 -1.8 -
0.23 
0 0 -0.52 
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Synthetic investigation 
It is a simple and expedient three component reaction with some modifications in dr. 
A.jread suresh
 
involving glyoxal, substituted aldehyde and substituted amine in the presence 
ammonium acetate for the synthesis of substituted imidazoles. 
Initially, it has been  investigated a three component reaction of glyoxal, 
benzaldehyde and aniline  in different solvent systems like methanol, ethanol, toluene and 
acetic acid and in presence of various bases like NH3, triethylamine, ammonium acetate, 
pyridine under reflux in 70
0
C to afford substituted imidazoles. The high yield of the product 
was obtained by the reaction mixture in acetic acid in presence of ammonium acetate.
 [203]
  
Synthetic scheme: 
 
                                    
 
 
 
 
 
 
 
 
 
 
 
 
 
R2       ALDEHYDE 
R1         PRIMERY 
AMINE 
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SYNTHETIC METHODS: 
Synthesis of Compound:
 [204,205]
  
A mixture of glyoxal (1.1 mmol), benzaldehyde (1.35 mmol) and aniline 
(1.75mmol) in acetic acid was reflux. After the complete disappearance of the both 
starting materials (monitored by TLC), ammonium acetate was added and the feflux 
was continued for 2½-3 hrs. The completion of the reaction is then confirmed by the 
TLC. Then its transfer to cold ice and getting precipitated the solid is then separated 
by vacuum filtration and washed with ethanol. The compound is recrystallized using 
ethanol.  
  
 
  
 
 
 
Mechanism for Formation of imidazole derivatives: [206]  
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TOXICITY PREDICTION [207,208]  
Toxicity predicted by the OSIRIS Property Explorer the online software of Thomas 
Sander, Actelion Pharmaceuticals Ltd., Gewerbestrasse 16, and 4123 Allschwil, Switzerland. 
The OSIRIS Property Explorer shown in this page is an integral part of Actelion's (1) inhouse 
substance registration system. It lets you draw chemical structures and calculates on-the-fly 
various drug-relevant properties whenever a structure is valid. Prediction results are valued 
and color coded. Properties with high risks of undesired effects like mutagenicity or a poor 
intestinal absorption are shown in red. Whereas a green color indicates drug-
conform behaviour. 
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SU-2 
SU-3 
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SU-4 
SU-5 
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SU-6 
SU-7 
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SU-8 
SU-9 
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INVITRO ANTI TUBERCLAR ACTIVITY [209,210]  
Anti-TB activity using Alamar Blue Dye 
 
 The anti-mycobacterial activity of compounds were assessed against M. 
tuberculosis using microplate Alamar Blue assay (MABA). 
 This methodology is non-toxic, uses a thermally stable reagent and shows good 
correlation with propotional and BACTEC radiometric method. 
 Briefly, 200µl of sterile deionzed  water was added to all outer perimeter wells of 
sterile 96 wells plate to minimized evaporation of medium in the test wells during 
incubation. 
 The 96 wells plate received 100 µl of the Middlebrook 7H9 broth and serial 
dilution of compounds were made directly on plate. 
 The final drug concentrations tested were 100 to 0.2 µg/ml. 
 Plates were covered and sealed with parafilm and incubated at 37ºC for five days. 
 After this time, 25µl of freshly prepared 1:1 mixture of Almar Blue reagent and 
10% tween 80 was added to the plate and incubated for 24 hrs.  
 A blue color in the well was interpreted as no bacterial growth, and pink color was 
scored as growth.  
 The MIC was defined as lowest drug concentration which prevented the color 
change from blue to pink.  
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IUPAC NAME            : Pyridine-4-carboxamide 
Molecular Formula     : C6H6N2O 
Formula Weight          : 122.12 
Description                 : White crystalline powder 
Melting point              : 128 
 
C 
Solubility                    :  ethanol 
IUPAC NAME                :         Pyridine-4-carboxamide 
Molecular Formula          :       C6H7N3O 
Formula Weight               :       137.13 
Description                       :      White crystalline powder 
Melting point                    :      197-200 
 
C 
Solubility                     :      ethanol 
ISONICOTINAMIDE 
          ISONIAZID                                                                     
ISONIAZID 
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IUPAC NAME           :         (2, 4-dinitrophenyl) hydrazine 
Molecular Formula     :       C6H6N4O4 
Formula Weight          :       198.13 
Description                  :      yellow crystalline powder 
Melting point               :       197-200 
 
C 
Solubility                     :      ethanol 
IUPAC NAME           :       ethane dials 
Molecular Formula     :      C2H2O2 
Formula Weight          :       58.04  
Description                  :      40%  aqueous solution 
Melting point               :       15 
 
C 
Solubility                     :      ethanol 
 2, 4-DINITROPHENYLHYDRAZINE 
GLYOXAL 
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IUPAC NAME           :       1, 3-benzothiazol-2-amine 
Molecular Formula     :      C7H 6 N2S 
Formula Weight          :       150.20 
Description                  :      yellow color powder 
Melting point               :      129 
 
C 
Solubility                     :      ethanol 
 
IUPAC NAME           :      2-bromo-5-methylpyridin-4-amine 
Molecular Formula     :      C6H 6BrN 
Formula Weight          :       172.20 
Description                  :    light yellow color powder 
Melting point               :      43 
 
C 
Solubility                     :      ethanol 
  2-AMINOBENZOTHIAZOLE 
2-BROMO-5-METHYLPYRIDINE 
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IUPAC NAME           :      2-bromo-5-methylpyridin-4-amine 
Molecular Formula     :      C6H 7NS 
Formula Weight          :       125.20 
Description                  :    color less liquid 
Melting point               :      23 
 
C 
Solubility                     :      ethanol 
IUPAC NAME            :      naphthalen-1-amine 
Molecular Formula     :      C10H 9N 
Formula Weight          :      143.20 
Description                 :    light purple 
Melting point              :     50 
 
C 
Solubility                    :      ethanol 
2- AMINOTHIOPHENOL 
   1- NAPHTHYLAMINE 
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IUPAC NAME           :      anthracen-9-amine 
Molecular Formula     :      C14H11N 
Formula Weight          :      300.20 
Description                  :    light purple 
Melting point               :     194 
 
C 
Solubility                     :      ethanol 
IUPAC NAME           :      5-nitrofuran-2-carbaldehyde 
Molecular Formula     :      C5H3NO5 
Formula Weight          :      141.20 
Description                  :    light brow 
Melting point               :     39 
 
C 
Solubility                     :      ethanol 
9- AMINOACRIDINE 
  5- NITROFURALDEHYDE 
                                                                                  Reactant profile 
 
Department of Pharmaceutical Chemistry Page 84 
 
                                          
 
                                                 
                                            
 
                                                  
IUPAC NAME           :     4-(dimethylamino)benzaldehyde 
Molecular Formula     :      C9H11NO 
Formula Weight          :     149.20 
Description                  :    white color crystal 
Melting point               :     75 
 
C 
Solubility                     :      ethanol 
IUPAC NAME           :     4-hydroxybenzaldehyde 
Molecular Formula     :      C7H6O2 
Formula Weight          :     122.20 
Description                  :   tan color powder 
Melting point               :     75 
 
C 
Solubility                     :      ethanol 
PARA-DIMETHYLAMINOBENZALDEHYDE 
4-HYDROXY BENZADEHYDE 
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IUPAC NAME           :   3-hydroxy-4-   
          methoxybenzaldehyde 
Molecular Formula     :      C8H8O3 
Formula Weight          :     152.20 
Description                  :   white crystal 
Melting point               :     83 
 
C 
Solubility                     :      ethanol 
IUPAC NAME           :   cyclohexanecarbaldehyde 
Molecular Formula     :      C7H12O 
Formula Weight          :     112.20 
Description                  :   colorless liquid  
Melting point               :    35 
 
C 
Solubility                     :      ethanol 
VANILINE 
CYCLOHEXANECARBOXALDEHYDE 
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IUPAC NAME           :  2-nitrobenzaldehyde 
Molecular Formula     :      C7H5NO3 
Formula Weight          :     151.20 
Description                  :   white color powder  
Melting point               :    43 
 
C 
Solubility                     :      ethanol 
IUPAC NAME           :  thiophene-2-carbaldehyde 
Molecular Formula     :      C5H4OS 
Formula Weight          :     112.20 
Description                  :   color less liquid  
Melting point               :    15 
 
C 
Solubility                     :      ethanol 
2 NITROBENZALDEHYDE 
THIOPHENECARBOXALDEHY
DE
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Molecular Formula  = C13H8N6O7 
Formula Weight  = 360.23862 
Composition               = C (43.34%) 
H(2.24%) N(23.33%) O(31.09%) 
Molar Refractivity  = 83.24 ± 0.5 cm
3
 
Molar Volume   = 199.0 ± 7.0 cm
3
 
Parachor                 = 621.0 ± 8.0 cm
3
 
Index of Refraction  = 1.776 ± 0.05 
Surface Tension   = 94.7 ± 7.0 
dyne/cm 
Density                = 1.80 ± 0.1 g/cm
3
 
Dielectric Constant  = Not available 
Polarizability      = 33.00 ± 0.5 10
-
SU-1 
Product profile 
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Molecular Formula   = C17H16N6O4 
Formula Weight              = 368.34674 
Composition              =  C(55.43%) H(4.38%) 
N(22.82%) O(17.37%) 
Molar Refractivity   = 98.21 ± 0.5 cm
3
 
Molar Volume   = 260.6 ± 7.0 cm
3
 
Parachor    = 729.9 ± 8.0 cm
3
 
Index of Refraction   = 1.677 ± 0.05 
Surface Tension   = 61.5 ± 7.0 dyne/cm 
Density    = 1.41 ± 0.1 g/cm
3
 
Dielectric Constant   = Not available 
Polarizability   = 38.93 ± 0.5 10
-24
cm
3
 
Monoisotopic Mass   = 368.123303 Da 
 
SU-2 
Product profile 
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Molecular Formula  = C16H11N3OS 
Formula Weight  = 293.34304 
Composition   = C(65.51%) H(3.78%) 
N(14.32%) O(5.45%) S(10.93%) 
Molar Refractivity  = 84.81 ± 0.5 cm
3
 
Molar Volume   = 208.1 ± 7.0 cm
3
 
Parachor   = 581.7 ± 8.0 cm
3
 
Index of Refraction  = 1.750 ± 0.05 
Surface Tensio n  = 61.0 ± 7.0 dyne/cm 
Density    = 1.40 ± 0.1 g/cm
3
 
Dielectric Constant  = Not available 
Polarizability   = 33.62 ± 0.5 10
-24
cm
3
 
Monoisotopic Mass  = 293.062282 Da 
 
SU-3
Product profile 
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Molecular Formula   = C16H14BrN3O2 
Formula Weight   = 360.20526 
Composition    = C(53.35%) H(3.92%) 
Br(22.18%) N(11.67%) O(8.88%) 
Molar Refractivity   = 88.12 ± 0.5 cm
3
 
Molar Volume   = 239.4 ± 7.0 cm
3
 
Parachor    = 634.7 ± 8.0 cm
3
 
Index of Refraction   = 1.657 ± 0.05 
Surface Tension   = 49.3 ± 7.0 dyne/cm 
Density    = 1.50 ± 0.1 g/cm
3
 
Dielectric Constant   = Not available 
Polarizability    = 34.93 ± 0.5 10
-24
cm
3
 
Monoisotopic Mass   = 359.026932 Da 
SU-4 
Product profile 
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Molecular Formula  = C15H17N5O4 
Formula Weight  = 331.32658 
Composition   = C(54.38%) H(5.17%) 
N(21.14%) O(19.32%) 
Molar Refractivity  = 85.41 ± 0.5 cm
3
 
Molar Volume   = 219.4 ± 7.0 cm
3
 
Parachor   = 633.6 ± 8.0 cm
3
 
Index of Refraction  = 1.706 ± 0.05 
Surface Tension   = 69.5 ± 7.0 dyne/cm 
Density    = 1.50 ± 0.1 g/cm
3
 
Dielectric Constant  = Not available 
Polarizability   = 33.85 ± 0.5 10
-24
cm
3
 
Monoisotopic Mass  = 331.128054 Da 
SU-5 
Product profile 
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Molecular Formula  = C17H17N3S 
Formula Weight  = 295.40198 
Composition   = C(69.12%) H(5.80%) 
N(14.22%) S(10.85%) 
Molar Refractivity  = 91.16 ± 0.5 cm
3
 
Molar Volume   = 253.9 ± 7.0 cm
3
 
Parachor   = 648.1 ± 8.0 cm
3
 
Index of Refraction  = 1.637 ± 0.05 
Surface Tension   = 42.3 ± 7.0 dyne/cm 
Density    = 1.16 ± 0.1 g/cm
3
 
Dielectric Constant  = Not available 
Polarizability   = 36.14 ± 0.5 10
-24
cm
3
 
Monoisotopic Mass  = 295.114318 Da 
SU-6 
Product profile 
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Molecular Formula  = C21H19N3 
Formula Weight  = 313.39566 
Composition   = C(80.48%) H(6.11%) 
N(13.41%) 
Molar Refractivity  = 99.72 ± 0.5 cm
3
 
Molar Volume   = 281.0 ± 7.0 cm
3
 
Parachor   = 718.9 ± 8.0 cm
3
 
Index of Refraction  = 1.627 ± 0.05 
Surface Tension   = 42.7 ± 7.0 dyne/cm 
Density    = 1.11 ± 0.1 g/cm
3
 
Dielectric Constant  = Not available 
Polarizability   = 39.53 ± 0.5 10
-24
cm
3
 
Monoisotopic Mass  = 313.157898 Da 
SU-7 
Product profile 
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Molecular Formula  = C16H13N5O6 
Formula Weight  = 371.30432 
Composition   = C(51.76%) H(3.53%) 
N(18.86%) O(25.85%) 
Molar Refractivity  = 92.07 ± 0.5 cm
3
 
Molar Volume  = 238.3 ± 7.0 cm
3
 
Parachor   = 689.6 ± 8.0 cm
3
 
Index of Refraction  = 1.699 ± 0.05 
Surface Tension   = 70.0 ± 7.0 dyne/cm 
Density    = 1.55 ± 0.1 g/cm
3
 
Dielectric Constant  = Not available 
Polarizability   = 36.50 ± 0.5 10
-24
cm
3
 
Monoisotopic Mass  = 371.086583 Da 
SU-8 
Product profile 
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Molecular Formula  = C22H14N4O2 
Formula Weight  = 366.37216 
Composition   = C(72.12%) H(3.85%) 
N(15.29%) O(8.73%) 
Molar Refractivity  = 106.91 ± 0.5 cm
3
 
Molar Volume   = 269.5 ± 7.0 cm
3
 
Parachor   = 748.8 ± 8.0 cm
3
 
Index of Refraction  = 1.723 ± 0.05 
Surface Tension   = 59.5 ± 7.0 dyne/cm 
Density    = 1.35 ± 0.1 g/cm
3
 
Dielectric Constant  = Not available 
Polarizability   = 42.38 ± 0.5 10
-24
cm
3
 
Monoisotopic Mass  = 366.111676 Da 
 
SU-9 
Product profile 
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Molecular Formula  = C13H10BrN3S 
Formula Weight  = 320.2076 
Composition   = C(48.76%) H(3.15%) 
Br(24.95%) N(13.12%) S(10.01%) 
Molar Refractivity  = 80.05 ± 0.5 cm
3
 
Molar Volume   = 202.7 ± 7.0 cm
3
 
Parachor   = 551.0 ± 8.0 cm
3
 
Index of Refraction  = 1.719 ± 0.05 
Surface Tension   = 54.5 ± 7.0 dyne/cm 
Density    = 1.57 ± 0.1 g/cm
3
 
Dielectric Constant  = Not available 
Polarizability   = 31.73 ± 0.5 10
-24
cm
3
 
Monoisotopic Mass  = 318.977872 Da 
SU-10 
Product profile 
 
Department of Pharmaceutical Chemistry Page 97 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Molecular Formula  = C14H9N3S2 
Formula Weight  = 283.37136 
Composition   = C(59.34%) H(3.20%) 
N(14.83%) S(22.63%) 
Molar Refractivity  = 82.55 ± 0.5 cm
3
 
Molar Volume   = 193.1 ± 7.0 cm
3
 
Parachor   = 548.3 ± 8.0 cm
3
 
Index of Refraction  = 1.799 ± 0.05 
Surface Tension  = 64.9 ± 7.0 dyne/cm 
Density   = 1.46 ± 0.1 g/cm
3
 
Dielectric Constant  = Not available 
Polarizability   = 32.72 ± 0.5 10
-24
cm
3
 
Monoisotopic Mass  = 283.023787 Da 
SU-11 
Product profile 
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Molecular Formula  = C14H13N3O4  
Formula Weight  = 287.27072 
Composition   = C(58.53%) H(4.56%) 
N(14.63%) O(22.28%) 
Molar Refractivity  = 72.88 ± 0.5 cm
3
 
Molar Volume   = 181.8 ± 7.0 cm
3
 
Parachor   = 526.8 ± 8.0 cm
3
 
Index of Refraction  = 1.734 ± 0.05 
Surface Tension   = 70.4 ± 7.0 dyne/cm 
Density    = 1.57 ± 0.1 g/cm
3
 
Dielectric Constant  = Not available 
Polarizability   = 28.89 ± 0.5 10
-24
cm
3
 
Monoisotopic Mass  = 287.090606 Da 
SU-12 
  
 
 
 Results and discussion 
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    RESULT AND DISCUSSION 
Already we discussed about the design and synthesis in materials an methods. Now 
we discuss about the result of Characterisation and in-vitro evaluation of synthesized 
compounds 
 
Physical properties of the synthesized compounds 
 
A) Melting point, Percentage yield.-Table-5 
                 
Compounds Melting Point 
O
C % Yield 
SU1 152-154 85 % 
SU2 148-150 82 % 
SU3 160-162 83 % 
SU4 150-152 86 % 
SU5 154-156 86 % 
SU6 158-160 84 % 
SU7 140-142 84 % 
SU8 170-172 82 % 
SU9 146-148 83 % 
SU10 156-158 82 % 
SU11 142-144 80% 
SU12 174-176 81% 
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B) TLC profile- Table-6 
 
 
 
 
. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Compounds Rf Solvent System 
SU1 0.42 Ethyl acetate: hexane (6:4) 
SU2 0.37 Ethyl acetate: hexane (6:4) 
SU3 0.38 Ethyl acetate: hexane (6:4) 
SU4 0.35 Ethyl acetate: hexane (6:4) 
SU5 0.27 Ethyl acetate: hexane (6:4) 
SU6 0.28 Ethyl acetate: hexane (6:4) 
SU7 0.39 Ethyl acetate: hexane (6:4) 
SU8 0.25        Ethyl acetate: hexane (6:4) 
SU9 0.30        Ethyl acetate: hexane (6:4) 
SU10 0.26        Ethyl acetate: hexane (6:4) 
SU11 0.24        Ethyl acetate: hexane (6:4) 
SU12 0.31        Ethyl acetate: hexane (6:4) 
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C) Solubility- Table-7 
 
 
Compounds Water Methanol Ethanol Ethyl acetate DMSO DMF 
SU1 Insoluble Soluble Soluble Soluble Soluble Soluble 
SU2 Insoluble Soluble Soluble Soluble Soluble Soluble 
SU3 Insoluble Soluble Soluble Soluble Soluble Soluble 
SU4 Insoluble Soluble Soluble Soluble Soluble Soluble 
SU5 Insoluble Soluble Soluble Soluble Soluble Soluble 
SU6 Insoluble Soluble Soluble Soluble Soluble Soluble 
SU7 Insoluble Soluble Soluble Soluble Soluble Soluble 
SU8 Insoluble Soluble Soluble Soluble Soluble Soluble 
SU9 Insoluble Soluble Soluble Soluble Soluble Soluble 
SU10 Insoluble Soluble Soluble Soluble Soluble Soluble 
SU11 Insoluble Soluble Soluble Soluble Soluble Soluble 
SU12 Insoluble Soluble Soluble Soluble Soluble Soluble 
 
The following experimental methods were used for the characterization of the 
synthesized compounds. 
1. Infra-Red Spectroscopy by Perkin Elmer FTIR Spectrometer using KBr pellets. 
2. 1H and 13C Nuclear Magnetic Spectroscopy by 500 MHZ Jeol using DMSO. 
3. The Mass Spectroscopy by Jeol GC mate. 
4. Melting Points by Open Capillary Tubes. 
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A) IR spectral data of the synthesized compounds- Table-8 
 
Compounds IR Absorption Region (cm
-1
) 
SU1 3338.64 cm
-1
 (Ar-CH), 1519.47 cm
-
 (C=C), 1152.16 cm
-1
 (C-N), 1022.75 
cm
-1
 (C=C-O-C). 
SU2 3308.37 cm
-1
 3056.69 cm
-1
 (Ar-CH), 1521.42 cm
-1
 (C=C), 1154.74 cm
-1
 (C-
N), 1016.04 cm
-1
 (C=C-O-C), 739.57 cm
-1
 (C-Cl). 
SU3 3309.63 cm
-1
, 3055.53 cm
-1
 (Ar-CH), 1522.76 cm
-1
 (C=C), 1155.74 cm
-1
 (C-
N), 1012.84 cm
-1
 (C=C-O-C), 578.63 cm
-1
 (C-Br). 
SU4  3060.70 cm
-1
 (Ar-CH),), 1509.22 cm
-1
 (C=C), 1155.29 cm
-1
 (C-N), 1012.93 
cm
-1
 (C=C-O-C), 1409.17 cm
-1
 (C-F). 
SU5  3052.13 cm
-1
 (Ar-CH), 1523.35 cm
-1
 (C=C), 1150.04 cm
-1
 (C-N), 1037.99 
cm
-1
 (C=C-O-C), 745.21 cm
-1
 (C-Cl). 
SU6  3064.5 cm
-1
 (Ar-CH), 1523.72 cm
-1
 (C=C), 1404.00 cm
-1
 (C-F), 1152.0 cm
-1
 
(C-N), 1020.48 cm
-1
 (C=C-O-C). 
SU7 3053.82 cm
-1
 (Ar-CH), 1518.98 cm
-1
 (C=C), 1153.95 cm
-1
 (C-N), 1020.96 
cm
-1
 (C=C-O-C), 575.55 cm
-1
 (C-Br). 
SU8 3060.14 cm
-1
 (Ar-CH), 1527.62 cm
-1
 (C-NO2), 1406.84 cm
-1
 (C=C), 1164.06 
cm
-1
 (C-N), 1019.68 cm
-1
 (C=C-O-C). 
           SU9 3046.07 cm
-1
 (Ar-CH), 2924.41 cm
-1
 (Ar-CH3), 2201.20  cm
-1
 (C≡N), 
1522.38 cm
-1
 (C=C), 1150.70 cm
-1
 (C-N), 1022.18 cm
-1
  (C=C-O-C). 
          SU10 3060.46 cm
-1
 (Ar-CH), 1512.94 cm
-1
 (C=C), 1250.18 cm
-1
 (O-CH3), 1152.03 
cm
-1
 (C-N), 1021.87 cm
-1
 (C=C-O-C). 
          SU11  3046.07 cm
-1
 (Ar-CH), 1514.47 cm
-1
 (C=C), 1264.32 cm
-1
 (O-CH3), 
1151.01 cm
-1
 (C-N), 1023.44 cm
-1
 (C=C-O-C). 
  
         SU12 
3055.53 cm
-1
 (Ar-CH), 1509.45 cm
-1
 (C=C), 1250.17 cm
-1
 (O-CH3), 1155.15 
cm
-1
 (C-N), 1025.17 cm
-1
 (C=C-O-C), 582.14 cm
-1 
(C-Br). 
Result and discussion 
 
Department of Pharmaceutical Chemistry Page 103 
 
IR spectrum of the synthesized compounds 
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A) 
1
H NMR Spectral Data of the Synthesized Compounds- Table-9 
 
Compounds 
1
H NMR Data (500 MHz, DMSO-d6) 
SU1  
δ 4.40 (s, 1H, -CH), 7.14 ( t , 1H, J = 6.9 Hz, Ar-H), 7.21 ( m, 2H, Ar-H), 
7.26 ( s, 2H, -), 7.28-7.32 (m, 2H, Ar-H), 7.38-7.41 ( m, 2H, Ar-H), 7.4 ( d, 
1H, J = 8.4 Hz,  Ar-H), 7.93 ( d, 1H, J = 8.4 Hz, Ar-H), 8.11 ( d, 1H, J = 
7.35 Hz, Ar-H), 11.96 ( br s, 1H, -NH,) 
 
SU2  
δ 4.46 (s, 1H, -CH), 7.13 ( t , 1H, J = 6.85 Hz, Ar-H), 7.20 ( t, 1H, J = 7.65 
Hz, Ar-H), 7.30 (s, 2H, -), 7.34-7.36 ( m, 2H, Ar-H), 7.45-7.48 ( m, 3H, Ar-
H), 7.92 ( d, 1H, J = 7.6 Hz, Ar-H), 8.11 ( d, 1H, J = 7.6 Hz, Ar-H), 11.96 ( 
br s, 1H, -NH, -  
SU3  
δ 4.44 (s, 1H, -CH), 7.13 ( t, 1H, J = 6.85 Hz, Ar-H), 7.20 ( t, 1H, J = 7.65 
Hz, Ar-H), 7.28 (s, 2H, -NH2,- 7.30 ( m, 2H, Ar-H), 7.47 ( d, 1H, J = 8.45 
Hz, Ar-H), 7.59 ( m, 2H, Ar-H), 7.91 ( d, 1H, J = 8.4 Hz, Ar-H), 8.10 ( d, 
1H, J = 6.9 Hz, Ar-H), 11.9 ( br s, 1H, -NH),  
 
SU4  
δ 4.45 (s, 1H, -CH), 7.13 ( t, 1H, J – 7.3 Hz, Ar-H), 7.19-7.23 ( m, 3H, Ar-
H),7.27 (s, 2H, - 7.35-7.37 ( m, 2H, Ar-H), 7.47 ( d, 1H, J = 8.55 Hz, Ar-H), 
7.92 ( d, 1H, J = 8.55 Hz, Ar-H), 8.10 ( d, 1H, J = 7.85 Hz, Ar-H), 11.95 ( 
br s, 1H, -NH,) 
 
SU5  
δ 4.87 (s, 1H, -CH), 7.13 ( t, 1H, J = 7.65 Hz, Ar-H), 7.20 ( t, 1H, J = 7.65 
Hz, Ar-H), 7.31 (s, 2H), 7.33-7.48 ( m, 5H, Ar-H), 7.91 ( d, 1H, J = 7.65 
Hz, Ar-H), 8.09 ( d, 1H, J = 7.7 Hz, Ar-H), 11.97 ( br s, 1H, -NH,)  
 
SU6  
δ 4.66 (s, 1H, -CH), 7.13 ( t, 1H, J = 6.85 Hz, Ar-H), 7.19-7.25 ( m, 5H, Ar-
H), 7.32 (s, 2H, 7.48 ( d, 1H, J = 7.65 Hz, Ar-H), 7.92 ( d, 1H, J = 8.4 Hz, 
Ar-H), 8.11 ( d, 1H, J = 6.9 Hz, Ar-H), 11.9 ( br s, 1H, -NH,  
 
SU7  
δ 4.47 (s, 1H, -CH), 7.13 ( t, 1H, J = 6.9 Hz, Ar-H), 7.20 ( t, 1H, J = 7.65 
Hz, Ar-H), 7.33 (s, 2H, -), 7.35-7.38 ( m, 2H, Ar-H), 7.46-7.51 ( m, 3H, Ar-
H), 7.91 ( d, 1H, J = 7.65 Hz, Ar-H), 8.11 ( d, 1H, J = 6.75 Hz, Ar-H), 11.98 
( br s, 1H, -NH,) 
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SU8  
 
δ 2.28 (s, 3H, -CH3), 4.34 ( s , 1H, -CH), 7.13 ( t, 1H, J = 7.65 Hz, Ar-H), 
7.19-7.21 ( m, 5H, Ar-H), 7.23 (s, 2H,), 7.48 ( d, 1H, J = 7.65 Hz, Ar-H), 
7.92 ( d, 1H, J = 8.4 Hz, Ar-H), 8.09 ( d, 1H, J = 6.73 Hz, Ar-H), 11.95 ( br 
s, 1H, -NH,) 
  SU9  
δ 2.38 (s, 3H, -CH3), 4.71 ( s, 1H, -CH), 7.13 ( t, 1H, J = 7.65 Hz, Ar-H), 
7.18 (s, 2H, -), 7.19-7.22 ( m, 5H, Ar-H), 7.48 ( d, 1H, J = 7.65 Hz, Ar-H), 
7.91 ( d, 1H, J = 7.65 Hz, Ar-H), 8.08 ( d, 1H, J = 6.7 Hz, Ar-H), 11.95 ( br 
s, 1H, -NH,) 
 
              SU10  
δ 2.9-3.04 (m, 6H, -CH3), 4.50 ( s, 1H, -CH), 7.13 ( t, 1H, J = 7.65 Hz, Ar-
H), 7.19-7.21 ( m, 5H, Ar-H), 7.23 (s, 2H, -NH) .48 ( d, 1H, J = 7.65 Hz, 
Ar-H), 7.92 ( d, 1H, J = 8.4 Hz, Ar-H), 8.10 ( d, 1H, J = 6.73 Hz, Ar-H), 
11.97 ( br s, 1H, -NH, ) 
              SU11 
 
 
 
δ 3.69 (s, 3H, -OCH3), 3.77 ( s, 3H, -OCH3), 4.79 ( s, 1H, -CH), 7.13-7.14 ( 
m, 1H, Ar-H), 7.18-7.20 ( m, 3H, Ar-H), 7.25 (s, 2H, -NH2, ), 7.47 ( d, 1H, J 
= 8.4 Hz, Ar-H), 7.89 ( d, 1H, J = 8.4 Hz, Ar-H), 8.09 ( d, 1H, J = 6.8 Hz, 
Ar-H), 11.95 ( br s, 1H, -NH,) 
 
               SU12 
 
 
δ 5.38 (s, 1H, -CH), 7.15 ( t , 1H, J = 6.85 Hz, Ar-H), 7.22 ( t, 1H, J = 7.65 
Hz, Ar-H),), 7.48-7.56 ( m, 5H, Ar-H), 7.89-7.98 ( m, 3H, Ar-H), 8.10 ( d, 
1H, J = 7.25 Hz, Ar-H), 8.38 ( d, 1H, J = 7.65 Hz, Ar-H), 11.97 ( br s, 1H, -
NH,) 
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1
H NMR Spectrum of the Synthesized Compounds 
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A) 
13
C NMR Spectral Data of the Synthesized Compounds- 
Table-10 
Compounds 
13
C NMR Data (500 MHz, DMSO-d6) 
SU1  
δ 19.09, 39.85, 40.01, 40.18, 56.44, 56.59, 84.62, 105.87, 112.82, 121.48, 
122.04, 123.18, 128.13, 128.24, 129.46, 129.83, 136.46, 143.59, 156.23, 
159.20. 
 
SU2  
δ 31.21, 55.99, 84.10, 105.80, 112.83, 119.33, 119.64, 121.51, 122.06, 
123.21, 125.00, 129.46, 129.94, 130.12, 132.86, 136.46, 142.5, 156.40, 
159.23. 
 
SU3  
δ 31.21, 55.93, 84.04, 105.79, 112.84, 119.32, 119.63, 121.44, 121.52, 
122.05, 123.22, 124.98, 129.95, 130.47, 132.39, 136.46, 142.98, 156.40, 
159.22. 
 
SU4  
δ 31.20, 56.33, 84.49, 105.84, 112.82, 116.15, 116.32, 119.37, 119.69, 
121.49, 122.03, 123.20. 125.00, 129.86, 130.16, 130.23, 136.46, 139.81. 
 
SU5  
δ 31.12, 54.96, 82.94, 105.78, 112.84, 119.14, 119.50, 121.54, 121.99, 
123.24, 124.99, 128.66, 129.90, 130.18, 130.65, 131.53, 133.01, 136.44, 
139.79. 
 
SU6  
δ 19.09, 54.88, 56.58, 82.92, 105.81, 112.84, 116.43, 116.60, 119.29, 
119.62, 121.51, 122.00, 123.20, 124.99, 125.61, 129.91, 130.47, 130.66, 
136.47. 
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SU7  
δ 31.21, 55.78, 83.84, 105.74, 112.85, 119.30, 119.62, 121.57, 122.02, 
122.61, 123.26, 124.95, 127.39, 130.02, 130.85, 131.25, 131.80, 136.44, 
146.26, 156.53, 159.29. 
 
SU8  
δ 31.20, 55.37, 83.38, 105.68, 112.87, 119.21, 119.53, 121.62, 122.04, 
122.68, 123.30, 123.45, 124.94, 130.17, 131.29, 135.10, 136.46, 145.75, 
148.62, 156.86, 159.45. 
 
SU9  
δ 21.23, 39.84, 40.13, 40.17, 56.57, 84.84, 105.91, 112.81, 119.48, 121.46, 
122.03, 123.17, 125.01, 128.05, 129.75, 130.01, 136.45, 140.67, 156.03, 
159.11.  
          SU10  
δ 31.20, 55.24, 56.31, 56.42, 83.39, 105.88, 112.82, 113.43, 119.10,  
119.50, 121.48, 121.95, 123.20, 125.02, 129.85, 136.43, 149.24, 149.64, 
156.64, 159.40. 
 
          SU11  
δ 31.22, 55.22, 83.15, 102.86, 105.85, 112.79, 112.95, 113.71, 119.07, 
119.42, 121.45, 122.16, 123.17, 125.03, 129.93, 136.43, 148.51, 156.75, 
159.39. 
 
 
SU12 
 
 
 
δ 39.85, 40.02, 40.18, 56.80, 84.95, 105.89, 112.85, 119.41, 119.75, 121.51, 
122.06, 123.20, 123.62, 125.06, 126.48, 126.87, 128.85, 129.36, 129.84, 
131.47, 134.19, 136.48. 
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13
C NMR Spectrum of the Synthesized Compounds 
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A) MASS spectral data of the synthesized compounds- Table-11 
 
Compounds Mass spectral data Molecular weight 
SU1 360(M
+
)7%303(B)100% 360 
SU2 369(M
+
1)8%338(B)100% 369 
SU3 294( M
+
)45%295( M
+
2)30%284(B)100% 293 
SU4 360( M
+
)12%361( M
+
2)100% 360 
SU5 331( M
+
)5%485(B)100% 331 
SU6 295( M
+
)55%255(B)100% 295 
SU7 313( M
+
)50%275(B)100% 313 
SU8 291( M
+
)90%269(B)100% 291 
SU9 371( M
+
)25%261(B)100% 371 
SU10 366( M
+
)70%452(B)100% 366 
SU11 273( M
+
2)10%232(B)100% 270 
SU12 320(M
+
)100%322( M
+
2)95%238(B)70% 320 
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IN-VITRO ANTI-TUBERCULAR ACTIVITY 
 Compounds were screened for invitro anti-tubercular activity (50, 100 µg/ml) by 
Microplate Alamar Blue Assay (MABA). 
 The anti-mycobacterial activities of compounds were assessed against M. tuberculosis 
using Microplate Alamar Blue Assay (MABA). 
 This methodology is non-toxic, uses a thermally stable reagent and shows good 
correlation with propotional and BACTEC radiometric method. 
 
STANDARD DRUG PHOTOGRAPH (MABA) 
 
 
 
  
  
  
  
  
 
 
 
 
Figure-13 
The stranded drug for MABA using pyrazinamide and ciprofloxacin and 
streptomycin. The minimum inhibitory concentration of pyrazinamide and 
ciprofloxacin shows 3.12micro gram/ml another stranded drug of streptomycin 
shows 6.25 micro gram/ml. 
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IMIDAZOLE NOVEL COMPOUND FROM 1 TO 12(MABA) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure-14 
 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
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 ANTI-TB RESULTS-Table-13 
 
 
 Sl. 
No.  
 
 
 
Sample 
code  
 
 
 100  
μg/ml  
 
 
  25 
μg/ml  
12.5 
μg/ml  
6.25 
μg/ml  
3.12 
μg/ml  
1.6 
μg/ml  
0.8 
μg/ml  
 
 
.  
/ l  
.  
/ l  
.  
/ l  
 
 
6.25 
μg/ml  
  
 
 
3.12 μg/ml  
 
 
1.6 μg/ml 
 
0.8 
μg/ml 
1 S S R R R R R R 
2 S S R R R R R R 
3 S S R R R R R R 
4 S S R R R R R R 
5 S S R R R R R R 
6 S S R R R R R R 
7 S S R R R R R R 
8 S S R R R R R R 
9 S S R R R R R R 
10 S S R R R R R R 
11 S S R R R R R R 
12 S S R R R R R R 
S-sensitive 
R-resistance 
All the 12 compounds exhibited good anti-tubercular activity with range 
of 50µg/ml. So Compounds SU1-SU12 was found to exhibit moderate anti-
tubercular activity. 
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                                                        SUMMARY 
 
 A target critical for the growth of Mycobacterium tuberculosis i.e., 1KPI was chosen. 
 A database of 100 molecules with high probability of inhibiting the target 1KPI were 
chosen by making changes to a   known inhibitor scaffold that is aryl substituted 
Imidazole 
 Docking of the 3D structure of these 100 entities against the 3D structure of 1KPI 
gave an insight about the energetics (molecular docking). 
 Of those 100 structures, only 12 structures which showed minimum binding energy 
were chosen for synthesis. 
 The purity of the synthesised compounds were confirmed by TLC and melting point 
and then characterized by IR, H
1
 NMR, C
13
 NMR and Mass spectroscopy. 
 The Pure compounds were screened for in-vitro Anti tubercular activity by Microplate 
Alamar blue Assay method. 
 The entire 12 synthesised compound showed sensitivity (Minimum Inhibitory 
Concentration) 50mcg/ml. 
 Toxicity risk assessment prediction was done for all the 12 compounds by Osiris 
property explorer developed by Acetlion Pharmaceuticals limited available online. 
                                                                 
 
 
 
 
 
                                                                                                     Summary 
 
Department of Pharmaceutical Chemistry Page 138 
 
 
                                       CONCLUSION 
All the 12 compounds gave G-score between -6.04to-10.00 kcal/mol. Pyrazinamide 
gave G-score of -5.6 for KPI, streptomycin gave G-score of  -7.4 for KPI and ciprofloxacin 
gave G-score of  -5.9 for KPI .there is   correlation between the score and activities of all the 
12 compounds which were tested and compared with the standard drugs. This goes to prove 
that 1KPI is a critical enzyme for anti-mycobacterial activity.so the fine tuning the structures 
of these 12compoundswill yield molecules with better antimycobacerial activity. 
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FUTURE SCOPE OF STUDY 
 The synthesized compounds should significant anti-tubercular activity 
in MABA assay method. Hence the anti-tubercular study would deserve for 
further investigations of in-vivo toxicity and in-vivo anti-tubercular studies. 
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